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Cytomegalovirus (CMV) is a ubiquitous herpes virus that generates a unique T cell response,
characterized by the maintenance of a high frequency of virus-specific T cells over the lifetime
of the host. This prolonged T cell response makes CMV an attractive vaccine platform. Our lab
has previously generated a recombinant murine CMV (MCMV) expressing a modified
melanoma antigen, MCMVgp100KGP, which protects mice from tumor challenge. In Chapter 3
of this current study, we hypothesized that CMV vectors expressing multiple tumor antigens
would be more effective vaccines in the treatment of melanoma. However, our data show that
novel MCMV vectors expressing two melanoma antigens do not delay tumor growth compared
to MCMVgp100KGP, highlighting the difficulty in targeting shared tumor antigens.
In Chapter 4, we sought to improve the efficacy of MCMVgp100KGP by combination
immunotherapy. Herein, we show that adoptive cell therapy enhances the antitumor effects of
MCMV-based vaccines. MCMVgp100KGP maintains adoptively transferred cells at higher
frequencies than an acute viral vector, but fails to eradicate established tumors. In response to
vaccination with MCMVgp100KGP, several immunosuppressive molecules including PD-L1,
Qa-1b, and IDO1 are upregulated within the tumor microenvironment, suggesting several
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mechanisms of tumor resistance. Surprisingly, blockade of these molecules did not improve the
antitumor activity of MCMVgp100KGP vaccination. This data further calls into question the
reliability of PD-L1, Qa-1b, and IDO1 expression as predictive markers for response to therapies
targeting these pathways. In the context of vaccination, these molecules may serve as indicators
of effective vaccination rather than predictive biomarkers for combination immunotherapy.
Lastly, this study also identifies a novel population of CD169+ tumor associated macrophages
(TAMs). In Chapter 5, we characterize a population of CD169+ TAMs found within the
melanoma tumor tissue. This population expresses higher levels of MHCII and CD80,
suggesting a potential to prime antitumor T cells. Preliminary data also suggests that CD169+
TAMs may preferentially phagocytose tumor cell fragments directly within the tumor bed.
Future work will determine the role of these TAMs in priming antitumor T cells and regulating
antitumor immunity.
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Chapter 1: Introduction
1. Evidence of Tumor-Immune Interactions
Immunotherapy of cancer has been a long-sought goal of scientists and oncologists which until
recently, had been largely discredited as a viable treatment modality for cancers unassociated
with infectious agents. Some of the earliest clinical studies utilizing a form of immunotherapy
for the treatment of cancer were performed by Dr. William Coley in the late 1800’s. Inspired by
a case of spontaneously regressing sarcoma following post-operative bacterial infection, Dr.
Coley attempted to cure his own patients, with limited success, using different bacterial toxins to
induce tumor regression.1 This early work hinted that manipulating the immune system could
have profound effects on cancer progression.
The importance of the immune system in cancer has also been highlighted by clinical
observations that immunocompromised patients have differing incidences of certain
malignancies.2,3 Following these observations, many studies have shown that malignant tissue is
often infiltrated by diverse classes of immune cells, including innate immune cells like
macrophages and neutrophils as well as adaptive immune cells like B lymphocytes and T
lymphocytes. Importantly, recent studies have shown that T cell infiltration is associated with a
better prognosis for several cancers, whereas myeloid cell infiltration tends to be associated with
poor prognosis.4-7 As will be discussed below, the most convincing data regarding the
importance of the immune system in the control of human cancer comes from clinical trials using
therapies designed to specifically modulate antitumor T cell responses.
Substantial preclinical data using animal models has shown the immune system influences
cancer progression. Pioneering work in the 1950’s showed that inbred mice could be immunized
1

against a chemically-induced tumor and confer protection against challenge by the same
tumor.8,9 Using several immunodeficient mouse lines, studies in the last two decades have
elucidated some of the machinery involved in tumor rejection, showing that lymphocytes,
perforin, and IFNγ are critically important for tumor immunity.10-12

2. Melanoma
2.1 Disease prevalence
Melanoma is a malignancy of melanocytes. It has been estimated that greater than 80,000
patients in the United States will be diagnosed with melanoma and over 9,000 patients will die
from this disease in 2017 alone.13 While most primary tumors occur in the skin, metastases often
seed the lungs, liver, bones, and brain of patients, making treatment much more difficult.14
Melanomas often arise from an accumulation of mutations induced by UV radiation from sun
exposure. Common mutations include activating mutations in BRAF (often BRAFV600E) and
KIT.15,16 These oncogenes can be targeted with molecular inhibitors with some clinical
success.17,18 Recently, antibodies targeting the T cell checkpoint molecules CTLA-4 and PD-1
have been approved for metastatic melanoma, marking the beginning of a new era in the
treatment of melanoma.19 These therapies will be discussed in greater detail below.
2.2 Melanoma antigens
Tumor antigens are peptides expressed in cancerous cells that can be recognized by the immune
system. They can be divided into two broad categories: the first category includes antigens
shared by both malignant cells and healthy tissue, and the second consists of antigens produced
as a result of nonsynonymous mutations in the cancer genome. Shared tumor antigens are
peptides found in both malignant and healthy tissues that are either overexpressed in transformed
2

cells or have limited expression in normal cells such as proteins expressed during embryonic
development that may be re-expressed in tumor tissue.20 Melanoma differentiation antigens
(MDA) like gp100, tyrosinase, Trp1, and Trp2 are proteins involved in melanosome function
whose expression are restricted to normal melanocytes and melanoma. In some patients with
melanoma, T cell responses to MDAs develop spontaneously.20-22 Because of this observation,
MDAs have been the target for many immunotherapies against melanoma, including vaccines
and adoptive cell therapy.23-26
A second class of tumor antigen has garnered much enthusiasm in recent years. Neoepitopes are
non-self-peptides formed as a result of nonsynonymous mutations within the cancer genome.27,28
Because these epitopes are produced as a result of mutations occurring only in the malignant cell,
they are theoretically highly specific to transformed tissue, making them intriguing targets for
immunotherapy. In theory, immune responses against neoepitopes should show limited side
effects due to reduced targeting of healthy tissue. Evidence for immune recognition of
neoepitopes (or tumor-specific immune recognition) has existed for many years.28-31 However,
until recently, technological limitations made it extremely difficult to definitely identify these
mutated peptides. With the great advances in sequencing technologies, significant effort has
been expended to map and predict immunogenic neoepitopes.27,32-36 While predicting which
mutations give rise to an immunogenic neoepitope remains a difficult task, clinic evidence for
the importance neoepitopes in immunotherapy exists. As will be discussed below, several
studies have suggested that the profound clinical results seen in some patients following
checkpoint blockade therapy or adoptive cell therapy may rely on enhancing the endogenous T
cell response to neoepitopes.37-42
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3. Immunotherapy of Melanoma
3.1 Vaccines
Several decades have passed since the identification of T cell epitopes in melanoma patients.
This discovery energized scientists and clinicians to attempt to generate or boost the T cell
responses against melanoma using vaccination. Early work focused on targeting MDAs like
gp100 and MART-1 in peptide vaccine formulations.24 While it was possible to detect MDAreactive T cells following vaccination, clinical responses were modest at best.43-45 These studies
and our own preclinical data highlight the difficulty in generating effective antitumor immune
responses against shared antigens. Several preclinical studies show that vaccination against
neoepitopes is possible and can delay tumor growth.34-36 Two clinical trials are currently
underway to determine if vaccination against neoepitopes might generate more dramatic clinical
responses in patients with melanoma (NCT01970358; NCT02035956).
3.2 Adoptive cell therapy
Pioneering work by Dr. Steven Rosenberg at the NCI has developed a form of immunotherapy
involving the transfer of large numbers of tumor-reactive lymphocytes into patients.26,46 This
modality of immunotherapy consists of two major methods. The first to be developed involves
culturing tumor infiltrating lymphocytes (TIL) obtained directly from tumor tissue to greatly
expand the TILs. The patient then receives a lymphodepleting regimen, consisting of
combination chemotherapy, before transfer of large numbers of cultured TIL to aid in the
expansion and persistence of transferred cells, which has been correlated with improved
responses.47,48 Patients then receive several doses of system IL-2 to aid the expansion of
transferred TIL.46,49 This therapy has shown up to 55% objective response rate in patients with
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metastatic melanoma, illustrating the potential power of this treatment modality and again
providing perhaps the most convincing clinical data that T cells can control tumor growth.49
Subsequent studies have shown that adoptively transferred TIL can recognize neoepitopes.37,38
This recognition likely explains the success of this form of immunotherapy because transfer of
autologous T cells enriched for reactivity to MDAs caused autoimmunity and had little clinical
benefit, while transfer of autologous T cells enriched for reactivity against neoepitopes shows
promising clinical activity.50,51
A second class of adoptive cell therapy involves engineering receptors in cells to redirect T cell
specificity prior to transfer into the patients. Several studies have tried to redirect patient T cells
to attack melanoma by transducing the expression of a traditional T cell receptor (TCR)
recognizing different MDAs. Morgan et al. engineered patient T cells to express a TCR
recognizing MART-1. Following lymphodepletion and cell transfer, two patients experienced
tumor regression.52 In a larger study in which T cells were engineered to express a TCR
recognizing MART-1 or gp100, objective tumor regression was seen in 30% and 19% of
patients, respectively. However, patients also experienced dermatitis, uveitis, and hearing loss
due to destruction of normal melanocytes.25 These results make engineered T cells targeting
shared antigens much less attractive.
An exception to this pessimism is seen in results from engineered T cells targeting the B cell
surface antigen, CD19. Studies targeting this antigen have utilized T cells engineered to express
a chimeric antigen receptor (CAR). CARs are artificial receptors consisting of the extracellular
variable regions of a tumor-antigen specific antibody and intracellular signaling domains
consisting of CD3ζ and costimulatory signaling domains. This artificial receptor allows
recognition of tumor antigen without the need for MHC presentation.53 CAR T cells targeting
5

CD19 have shown impressive results in patients with B Cell Acute Lymphoblastic Leukemia.5457

Current research is focused on improving the persistence and trafficking of CAR T cells while

increasing their resistance to tumor microenvironment immunosuppression.53 Extending these
technologies to target other tumor types is also a major focus of research. However, finding
relevant targets on other solid tumors will likely be difficult because as discussed before, major
toxicities are likely when targeting shared antigens.
3.3 Checkpoint Inhibitors
With the recent FDA approval of several T cell checkpoint inhibitors, cancer therapy has entered
a new era in which immunotherapy joins surgery, radiation, and chemotherapy as pillars of
clinical oncology. Immune checkpoint inhibitors are thought to work by blocking the interaction
of inhibitory receptors on the surface of antitumor T cells with their respective ligands, thereby
“releasing the brake” on antitumor T cells and allowing tumor destruction.
Ipilimumab, an antibody targeting CTLA-4, was the first checkpoint inhibitor approved by the
FDA after it was shown to improve overall survival in patients with metastatic melanoma.58,59
CTLA-4 (Cytotoxic T Lymphocyte Associated Protein 4) is an inhibitory receptor expressed on
the surface of T cells during activation. It recognizes CD80 and CD86 on antigen presenting
cells during activation, and it binds with them with higher affinity than the costimulatory
receptor CD28 which is also expressed on the surface of T cells.60-62 CTLA-4 is therefore
believed to limit the availability of CD80 and CD86 for CD28 costimulation during T cell
activation. Based on these observations, Leach et al. first showed the antitumor effects of
CTLA-4 blockade in murine tumor models.63 It has since been discovered that CTLA-4 is also
highly expressed on Foxp3+ regulatory T cells (Treg), and CTLA-4 signaling in Tregs can
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increase their immunosuppressive effects.64 Subsequent studies have suggested that the clinical
responses to CTLA-4 blockade are likely due to effects on both effector T cells and Tregs.65
Shortly after the approval of ipilimumab, several antibodies targeting the PD-1/PD-L1 axis were
also shown to significantly improve survival in patients with metastatic melanoma.66,67 PD-1
(Programmed Cell Death Protein 1) is a surface receptor expressed by activated T cells, B cells,
and some myeloid cells.68 PD-1 signaling dampens T cell proliferation and cytokine secretion
primarily by reducing costimulatory signals through CD28.69,70 PD-1 has two major ligands,
PD-L1 and PD-L2. PD-L1 is expressed on a diverse set of cells including immune cells,
endothelial cells, and malignant cells.71 PD-L2 expression, on the other hand, is limited mainly
to myeloid cells.71 PD-L1 is upregulated in tumor tissue in response to T cell infiltration and
IFNγ release, and the interaction between PD-1 and PD-L1 protects tumors from T cell-mediated
destruction.72-74
Unfortunately, not all patients respond checkpoint inhibitors. In the case of PD-1 blockade,
several studies have suggested that PD-L1 expression within the tumor can be predictive of
clinical responses.75-77 In responders, PD-L1 is likely expressed as a consequence of T cell
infiltration while also negatively regulating T cells within the tumor microenvironment.77 If so,
what are the target antigens for these T cells? Several studies have shown that clinical response
to PD-1 or CTLA-4 blockade correlates with mutational burden and predicted neoepitope
frequency.39-42,78,79 Thus, it is likely that tumor regression following checkpoint inhibition
requires a T cell response against neoepitopes in most cases.

7

4. T Cell Response to Cytomegalovirus
4.1 Cytomegalovirus is a prevalent herpesvirus
Cytomegalovirus (CMV) is a DNA, enveloped β-herpes virus that infects more than 60% of
Americans over the age of 50.80 Like other members of the herpes virus family, CMV is never
cleared from the infected host. Following an asymptomatic acute infection, CMV enters a state
of latency in several organs including lungs, liver, spleen, and brain.81 During this period, few
infectious viral particles are produced yet viral transcription is detectable.82,83 For most
immunocompetent adults, CMV never produces symptomatic disease, instead relying on periods
of asymptomatic reactivation and shedding for spread to new hosts. However, CMV can
produce severe pathology in neonates and immunocompromised adults due to unrestrained viral
spread.84-88 More recent work has also suggested that CMV can undergo subclinical reactivation
in critically ill immunocompetent hosts, and this reactivation is associated with worse outcomes.
However, the exact mechanism for this association has not been elucidated.89-93
4.2 T cell memory inflation
The immune response to CMV has become an increasingly popular research topic in recent
years. Given the persistent nature of the virus, the host immune system answers the infection
with a unique T cell response termed “memory inflation” in which a high frequency of virusspecific lymphocytes persists in blood, lymphoid tissue, and non-lymphoid tissue over the
lifetime of the host. This phenomenon has been best characterized with CD8+ T cells in humans,
non-human primates, and rodents (Figure 1-1).94-96 In healthy CMV-seropositive humans, CMVspecific CD8+ T cells can represent up to 20-30% of circulating CD8+ T cells, and these cells
display an effector memory or terminally differentiated effector phenotype characterized as
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CD45RA-CCR7- or CD45RA+CCR7-, respectively.95-97 A similar accumulation of CMVspecific CD4+ T cells seems to occur in humans albeit at lower frequencies.95,97,98 It has been
postulated that having such a large proportion of the immune system responding to CMV may
cause premature aging of the immune system and limit the repertoire of non-CMV-specific T
cells.99-101 More work is needed to fully elucidate the role of CMV in aging.
Murine Cytomegalovirus (MCMV) is a well-established model for human CMV infection with
similar cellular tropisms and a similar host immune response.83,94,102 As such, it has been an
invaluable tool for learning more about the inflationary response to CMV viruses. Similar to
human CMV, following an acute infection, MCMV spreads to several tissues including lungs,
salivary glands, spleen, and liver, among others.102,103 Within two weeks, viral load decreases
significantly in most tissues except salivary gland where the viral load kinetics are delayed.103
True latency defined by absence of detectable viral transcripts is established within 4 months of
infection in Balb/c mice and probably earlier in C57BL/6 mice which are more resistant to
MCMV.91,104
Like human CMV, MCMV elicits an inflationary CD8+ T cell response characterized by large
frequencies of virus-specific T cells that are maintained over the lifetime of the host.94,105,106
These cells display an effector memory phenotype characterized by high expression of KLRG1
and low expression of the IL-7 Receptor α, CD127.105 In contrast to other persistent viral
infections that maintain high frequencies of virus-specific T cells, MCMV inflationary T cells do
not become “exhausted”, as they display low expression of PD-1 and retain the capacity to
produce IFNγ and TNFα following peptide stimulation.105,107 The reason for this is likely the
rapid turnover of individual cells within inflationary cell populations. While the frequency of
inflationary T cells may remain relatively constant over time, individual cells within this
9

population do not persist over the course of the infection.105 The current model suggests that the
majority of inflationary T cells displaying an effector memory phenotype are not long-lived but
are constantly replaced by proliferating naïve cells or traditional memory cells that have recently
encountered viral antigen.94,105 A recent study by Quinn et al. suggests that within the
inflationary pool, a long-lived population of KLRG1-CD27+ “memory-like” cells can be
repeatedly stimulated to produce progeny with an effector memory phenotype.108 Thus, it is
likely that the vast majority of inflationary T cells are short-lived cells constantly replaced by
proliferating memory or naïve cells. Because CMV is only sporadically transcriptionally active
during latency, inflationary CMV-specific T cells likely only rarely encounter viral antigen.94,109
Sporadic stimulation by antigen may explain why MCMV inflationary T cells do not become
exhausted while T cells seen in other chronic infections do.
Importantly, not all MCMV-specific T cells undergo inflationary expansion. In C57BL/6 mice,
CD8+ T cells recognizing the peptides m38, m139, and ie3 undergo inflationary
expansion.94,105,106 Other CD8+ T cells recognizing the peptides m45 and m57 show more
traditional CD8+ T cell kinetics characterized by rapid expansion in the first week of infection
followed by dramatic contraction and maintenance of a low-frequency of central memory cells in
lymphoid tissues.94,105,106 The exact mechanisms determining whether an epitope generates an
inflationary or non-inflationary T cell response are still incomplete. However, several studies
have attempted to address this issue. It is now clear that the promoter regulating the expression
of the peptide is crucial for determining what kind of T cell response will form. Dekhtiarenko et
al. showed that a recombinant MCMV engineered to express an HSV-1 epitope fused to ie2, a
peptide that is expressed early during MCMV reactivation, generated an inflationary T cell
response to the HSV-1 epitope, whereas a virus engineered with the HSV-1 epitope fused to the
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m45 peptide, which elicits a traditional T cell response, generated a non-inflationary T cell
response.110 This data supports the model that inflationary T cells are stimulated by viral
peptides that are expressed in latency or early during reactivation. Thus, a promoter expressed
during latency or early reactivation is likely required to elicit an inflationary T cell response.
4.3 Cytomegalovirus as a vaccine vector
Historically, vaccines have largely focused on generating long-lived humoral immunity by
exposing vaccinated individuals to short bursts of target peptide along with adjuvant. While
neutralizing antibodies may be effective against some extracellular pathogens, they are clearly
ineffective for other microbes that establish intracellular reservoirs. For this reason, vaccine
formulations aimed at generating long-lived T cell responses have been a major focus of
research.111
Cytomegalovirus has several properties making it an attractive vaccine platform. 1) As
discussed above, CMV generates a lifelong T cell response characterized by persistence of a
large population of functional T cells in both lymphoid and non-lymphoid tissue. Thus,
engineering a CMV vector generating a similar T cell response against another antigen of interest
could potentially provide lifelong immunity without the need for multiple vaccinations. 2) CMV
utilizes many immunoevasive mechanisms to avoid elimination from infected hosts. These
mechanisms also prevent neutralizing immunity, allowing reinfection of individuals with
multiple strains of CMV.112-115 Thus, unlike vaccine vectors against other microbes, CMV-based
vaccines could be used in CMV-seronegative and –seropositive patients alike, and vaccination
with one CMV-based vaccine should not diminish the response generated by a second CMVbased vaccine. 3) Another critical and intriguing characteristic of CMV-based vaccines is that a
fully functional virus is not required to generate inflationary T cell responses. As discussed
11

above, CMV is a human pathogen that causes severe disease in immunocompromised patients
and may impact critically-ill immunocompetent patients as well.84-87,89,90 Vaccinating patients
with a live virus therefore increases risks for some patients. However, a critical study in mice
showed that a recombinant MCMV virus incapable of spreading from cell-to-cell after the initial
infection still produced an inflationary T cell response.116,117 Thus, CMV-based vaccines can be
engineered to dramatically reduce the chances of CMV pathology due to viral reactivation, while
also maintaining an effective inflationary T cell response. These properties make CMV an
attractive and relatively safe platform for vaccine development.
Several groups have generated recombinant Cytomegalovirus-based vaccines against different
infectious agents. Tsuda et al. showed that a recombinant MCMV expressing an epitope from
Ebolavirus could generate an inflationary CD8+ T cell response against the Ebola epitope and
vaccination with this recombinant MCMV protected mice from challenge with Ebolavirus.118,119
Similarly, other groups have shown that MCMV-based vaccines for Influenza and Respiratory
Syncytial Virus can produce inflationary T cell responses and protect mice from challenge with
these pathogens.120,121 Another study showed that an MCMV-based vaccine can protect mice
against challenge with Mycobacterium Tuberculosis even though the vaccine generates a modest
inflationary T cell response.122 Perhaps the most promising studies using CMV-based vaccines
have shown that recombinant rhesus Cytomegalovirus expressing epitopes from Simian
Immunodeficiency Virus (SIV) can elicit impressive protection against challenge with SIV.123,124
In this case, the efficacy of the vaccine may rely on non-traditional CD8+ T cell responses that
recognize both MHC-I and MHC-II restricted epitopes.125 Future studies will undoubtedly
continue to develop CMV-based vaccines for infectious disease, particularly for HIV.
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Given the properties of CMV-based vaccines described above, our group and others have been
interesting in developing CMV-based vaccines against cancer. The first study to test this idea
was published by Klyushnenkova et al. in 2012. In this study, mice vaccinated with a MCMV
vector expressing an epitope from Prostate Specific Antigen (PSA) developed inflationary CD8+
T cell responses against PSA and showed delayed tumor growth in a model of prostate cancer.126
Interestingly, the same vector expressing full-length PSA induced a weaker PSA-specific CD8+ T
cell response which correlated with reduced tumor control compared to the vector expressing the
CD8 epitope alone. The authors speculate that the full length peptide may generate regulatory T
cells through CD4 epitope expression; however, the exact reason for the discordant results is
unknown.126 Another study by Xu et al. in 2013 generated a CMV-based vaccine for melanoma.
In this study, a MCMV vector expressing the melanoma differentiation antigen, Trp2, did not
elicit a detectable T cell response to Trp2. Instead, mice vaccinated with this vector developed
an antibody response to Trp2 which had modest effects on B16 melanoma tumor growth.127 A
more recent study by the same group showed that a MCMV vector expressing a modified CD8
epitope for the melanoma antigen, gp100, could elicit a gp100-reactive CD8+ T cell response, but
this had only modest effects on tumor growth following intraperitoneal vaccination.
Intratumoral vaccination, however, completely eradicated some B16 melanomas, but
surprisingly, this effect was less dependent on viral expression of the tumor antigen, as MCMV
expressing gp100 had similar effects as wild type MCMV injected directly into the tumor.128
Our lab has also previously generated a MCMV-based vaccine for melanoma. This MCMV
vector (MCMVgp100KGP) contains the full-length gp100 peptide sequence which has been
mutated at 3 amino acids within the well-characterized CD8+ T cell epitope gp10025-33
(EGSRNQDWL=>KGPRNQDWL). MCMVgp100KGP induces a CD8+ T cell response against
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the native gp10025-33 epitope in vaccinated mice and significantly delays tumor growth in a lung
metastatic model of B16F10 melanoma.129,130 The major focus of my thesis has been to explore
methods for improving the antitumor efficacy of MCMV-based vaccines by creating novel
vectors expressing multiple tumor antigens and combining MCMV-based vaccines with other
immunotherapies targeting immunosuppressive pathways found in the tumor microenvironment
(Figure 1-2).
Figures:

Figure 1-1: Inflationary CD8+ T cells recognizing MCMV antigens accumulate over the
lifetime of the host. C57BL/6 mice were infected with 105 MCMV Smith strain. CD8+ T cells
recognizing the inflationary epitope, m38, are maintained at high frequencies over the lifetime of
the host, while T cells recognizing a non-inflationary epitope, m45, display a traditional T cell
response. Frequencies of epitope-specific T cells were determined by staining peripheral blood
leukocytes with m38- and m45-peptide tetramers.
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Figure 1-2: Rationale for combining CMV-based tumor vaccines with other
immunotherapies. 1) CMV-based vaccines allow persistent presentation of tumor antigen in
peripheral tissues to allow continuous stimulation of tumor-specific T cells. 2) Activated tumorspecific T cells migrate into tumor microenvironment. 3) Tumors utilize many strategies to limit
antitumor T cell activity in the tumor microenvironment including accumulation of
immunosuppressive immune cells, expression of inhibitory ligands, local tryptophan depletion,
and tissue hypoxia, among others. Targeting these immunosuppressive pathways may enhance
the efficacy of CMV-based vaccines.
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Chapter 2: Materials and Methods
2.1 Mice
Female C57BL/6 mice (6-8 weeks old) were purchased from Charles River (Frederick, MD). All
mice used in these studies were between 6 and 12 weeks of age at the start of the experiment.
Breeding pairs of PMEL mice (B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J) were purchased from the
Jackson Laboratory (Bar Harbor, ME) and bred in house. Mice were housed at the University of
Connecticut Health Center in a pathogen-free facility, and all experiments were performed with
approval by the University of Connecticut Health Center Institutional Animal Care and Use
Committee.
2.2 Cell Lines and Viruses
B16F10 and B16ova were provided by Dr. Leo Lefrançois (University of Connecticut Health
Center). B16F10-RFP was purchased from AntiCancer, Inc. (San Diego, CA). B16F10 cells
were cultured in DMEM media (Life Technologies) supplemented with 10% fetal bovine serum
(Life Technologies), 1mM sodium pyruvate (Life Technologies), 1% non-essential amino acids
(Life Technologies), and 1% Penicillin/Streptomycin (Life Technologies). B16ova cells were
cultured in B16F10 culture media supplemented with 500 µg/mL G418 (Life Technologies).
B16F10-RFP were cultured according to supplier’s instructions in RPMI 1640 media (Life
Technologies) supplemented with 10% fetal bovine serum, 2mM L-Glutamine (Life
Technologies), 1% Penicillin/Streptomycin, and 400µg/mL G418. Mouse embryonic fibroblasts
(MEFs) were cultured in DMEM media supplemented with 5% fetal bovine serum, 1% nonessential amino acids, 1% sodium pyruvate, 2mM L-Glutamine, and 1% Penicillin/Streptomycin.
M2-10B4 (a kind gift from Dr. Christopher Snyder; Thomas Jefferson University) were cultured
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in RPMI-1640 media supplemented with 10% fetal bovine serum, 2mM L-Glutamine, and 1%
Penicillin/Streptomycin.
MCMVova was provided by Dr. Carol Wu (University of Connecticut Health Center). Wild
type MCMV, MCMVgp100, and MCMVgp100KGP were previously generated in the lab by Dr.
Zhijuan Qiu using the MCMV BAC pSM3fr-MCK-2fl provided by Dr. Barbara Adler (LudwigMaximilians-University Munich, Germany).129 Briefly, the full-length murine gp100 coding
sequence or the altered sequence (gp100KGP) was inserted into the MCMV ie2 locus under the
control of the HCMV ie1 promoter.129 Previously generated viruses (WT MCMV,
MCMVgp100, and MCMVgp100KGP) were expanded using murine embryonic fibroblasts or
the bone marrow stromal cell line, M2-10B4, as previously described.131
2.3 Generating MCMVgp100KGP-Trp2 and MCMVgp100KGP-Trp2-2M
Recombinant MCMV viruses expressing gp100KGP and the melanoma antigen Trp2 were
generated by BAC recombineering using galK positive/negative selection.132 The MCMV BAC
pSM3fr-MCK-2fl was provided by Dr. Barbara Adler (Ludwig-Maximilians-University Munich,
Germany). pSM3fr-MCK-2fl-gp100KGP was generated as previously described.129 To generate
pSM3fr-MCK-2fl-gp100KGP-Trp2 and pSM3fr-MCK-2fl-gp100KGP-Trp2-2M, a two-step
galK selection in the SW102 bacterial strain (provided by Biological Resources Branch, National
Cancer Institute Preclinical Repository) was used to insert the Trp2 or Trp2-2M coding sequence
along with an Internal Ribosomal Entry Sequence (IRES) just downstream of the gp100KGP
coding sequence. To begin, a galK targeting cassette was generated by amplifying pgalK
(provided by Biological Resources Branch, National Cancer Institute Preclinical Repository)
using primers galK-targeting-F 5’-ACAGCCCGCTCCTCAGTGGACAGCAGGT CTGAGTCG
ACGGTACCGCGGGCCCTGTTGACAATTAATCATCGGCA-3’ and galK-targeting-R 5’17

AAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCA GTTATCA
GCACTGTCCTGCTCCTT-3’. Underlined sequences are homologous to pgalK and nonunderlined sequences are homologous to pSM3fr-MCK-2fl-gp100KGP. A first recombineering
step using galK positive selection was used to generate pSM3fr-MCK-2fl-gp100KGP-galK. The
Trp2 coding sequence was amplified from a plasmid containing the Trp2 gene (Origene) with
primers containing the restriction sites for NcoI and SalI, Trp2-F 5’CCATGGGCCACCATGGGCCTTGTGGGATGGG-3’ and Trp2-R 5’- GTCGACCTAGGCT
TCCTCCGTGTATC-3’. Sequences in italics correspond to restriction sites for NcoI and SalI,
respectively, and underlined sequences are homologous to Trp2 gene encoding plasmid. Trp2
was cloned into pMigR just downstream of the EMCV IRES sequence generating pMigR-Trp2.
To produce pMigR-Trp2-2M, site-directed mutagenesis was performed on pMigR-Trp2-2M
using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and primers
Trp2-2M-F 5’- ACACAAAAAAGTCATACATGCTGCAGTTGGCGATCTG-3’ and Trp2-2MR 5’- CAGATCGCCAACTGCAGCATGTATGACTTTTTTGTGT-3’. Mutation of the Trp2
CD8 T cell epitope was confirmed by sequencing. Finally, to generate pSM3fr-MCK-2flgp100KGP-Trp2 and pSM3fr-MCK-2fl-gp100KGP-Trp2-2M, a second recombineering step
using galK negative selection was performed to replace the galK sequence with our target
construct. To do this, targeting cassettes containing IRES-Trp2 or IRES-Trp2-2M were
amplified using primers IRES-trp2-targeting-F 5’ACAGCCCGCTCCTCAGTGGACAGCAGGTCTGAGTCGACGGTACC
GCGGGCCTCTCGAGGTTAACGAATTCCGCCCCCCCC-3’ and IRES-trp2-targeting-R 5’AAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCAGTTACTAGGCT
TCCTCCGTGTATCTCTTGCTGCT-3’. Underlined sequences are homologous to pSM3fr-

18

MCK-2fl-gp100KGP and the non-underlined sequences are homologous for pMigR-Trp2. To
increase the efficiency of recombineering, the homologous arms of the targeting cassettes IRESTrp2 and IRES-Trp2-2M were extended using a second amplification step containing 5’ and 3’
overlapping homologous arms. These overlapping homologous arms were generated by
amplifying segments from pSM3fr-MCK-2fl-gp100KGP using the primers homologyarm1-F 5’TTGAGCTGACTGTGTCCTGC-3’ and homologyarm1-R 5’- CAGACCTGCTGTCCACT
GAG-3’ for one reaction and homologyarm2-F 5’- AGCCATACCACATTTGTAGAGGT-3’
and homologyarm2-R 5’- GGGCTTCTAATTACGTGACGC-3’ for the second reaction. The
products of these two PCR reactions were then used to amplify the targeting cassettes IRES-Trp2
or IRES-Trp2-2M, generating the targeting cassettes with roughly 400-500bp 5’ and 3’
homology to pSM3fr-MCK-2fl-gp100KGP. This extended targeting construct was then used in
the final recombineering step to replace the galK construct within pSM3fr-MCK-2fl-gp100KGPgalK, generating pSM3fr-MCK-2fl-gp100KGP-Trp2 and pSM3fr-MCK-2fl-gp100KGP-Trp22M. Correct insertion was verified by restriction enzyme digest and by sequencing of the target
insertion sequence. To produce live virus, MEFs were transfected with pSM3fr-MCK-2flgp100KGP-Trp2 or pSM3fr-MCK-2fl-gp100KGP-Trp2-2M using X-tremeGENE 9 DNA
Transfection Reagent (Roche). Each recombinant virus was passaged in vitro at least three times
before use in vivo.
2.4 Western blot
MEFs were infected with WT MCMV, MCMVgp100KGP-Trp2, or MCMVgp100KGP-Trp22M. Two days later, cells were harvested and lysed RIPA lysis buffer. Uninfected MEFs and
B16F10 cells were also harvested as controls. Total protein content was quantified using Pierce
BCA Protein Assay Kit (ThermoScientific). 15µg protein was mixed with 4X Laemmli Sample
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Buffer (Bio-Rad), boiled for 5 minutes, and run on 10% Mini-PROTEAN TGX Precast Gel (BioRad). Protein was transferred to nitrocellulose membrane overnight by wet electrotransfer. The
membrane was blocked for 1 hour in 5% Milk in TBS-T (0.1% Tween 20 in Tris-buffered saline
(Bio-Rad)) followed by overnight incubation with anti-Trp2 (Abcam ab740473). After washing
with TBS-T, membrane was incubated with anti-Rabbit-HRP for 1 hour. Secondary was washed
away with TBS-T and bands were detected by chemiluminescence (ThermoScientific). The
same membrane was then stripped with Restore Western Blot Stripping Buffer
(ThermoScientific) and reprobed with anti-gp100 (Abcam ab137078) and anti-β tubulin (Cell
Signaling 2128).
2.5 Ex vivo peptide stimulation
Splenocytes were stimulated with 1µg/mL murine gp100 peptide or 1µg/mL PMA/Ionomysin
(BD Biosciences) for 5 hours at 37°C in the presence of Brefeldin A (BD Biosciences) followed
by intracellular staining for IFNγ.
2.6 In vitro culture of PMEL cells
Splenocytes from PMEL mice were cultured in RPMI containing 10% fetal bovine serum, 1%
sodium pyruvate, 2% HEPES, 1% L-Glutamine, 100µM non-essential amino acids, 0.05mM 2mercaptoethanol, and 1% penicillin/streptomycin supplemented with 1µg/mL human gp100
peptide and 30IU/mL recombinant human IL-2. Cells were split after daily after two days and
harvested on day 7 of culture for adoptive transfer in tumor-bearing mice.
2.7 B16-specific ELISA
96-well plates were coated overnight with B16F10 lysate. After blocking with 5% BSA for 1
hour, dilutions of sera from unvaccinated mice or mice vaccinated with recombinant MCMV
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were added to individual wells for 2 hours. Wells were then incubated with HRP-conjugated
anti-mouse IgG for 1 hour. 3,3’,5,5’-tetramethylbenzidine was then added to each well and plate
was read at 492 nm in colorimetric plate reader.
2.8 Tumor challenge experiments
Female C57Bl/6 mice received an intradermal or intravenous injection of 105 B16F10 or
B16RFP or 3x105 B16ova. Mice were then vaccinated with WT or recombinant MCMV
depending on the experiment. For intravenous tumor inoculation studies, mice were euthanized
2-3 weeks after challenge, lungs excised, and tumor nodules were counted manually under a
dissecting microscope. In some experiments, splenocytes corresponding to 105 CD8+ PMEL
cells from naïve PMEL mice or 105 CD8+ OT-I cells from OT-I/Rag- mice were transferred into
naïve WT tumor-bearing mice two hours prior to vaccination with WT or recombinant MCMV.
Intradermal tumor growth was monitored every 2-3 days by measuring length and width of the
tumor using calipers and multiplying to calculate surface area. Mice were euthanized when
tumors reached >100 mm2 or ulcerated. In some experiments, tumor-bearing mice also received
i.p. injections of anti-PD1 antibody (RMP1-14; BioXcell), anti-Qa-1b (4C2.4A7.5H11;
BioXcell), anti-CTLA4 (UC10-4F10-11; BioXcell) or isotype controls. For IDO inhibition
experiments, the IDO inhibitor 1-methyl-D-tryptophan (1-MT; Sigma) was dissolved in 1M
NaOH, diluted to 2mg/mL in drinking water, and pH was adjusted to 9 using 1M HCl. Control
mice received water adjusted to pH 9 without 1-MT. Water was replaced every 4-5 days.
2.9 Flow cytometry
Tumor tissue was mechanically dissociated and digested in 0.7mg/mL Collagenase D (Roche)
and 3mg/mL DNase I (Roche) for 30-45 minutes to obtain single cell suspension. For
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experiments looking at tumor infiltrating leukocytes, TIL were isolated using Percoll gradient
prior to staining. For experiments looking at B16RFP+ tumor cells, cells were stained
immediately after digestion for 20 minutes. Cells were blocked with anti-CD16/32 (clone 93;
Biolegend) prior to surface staining. For intracellular staining, cells were fixed and
permeabilized using Cytofix/Cytoperm (BD Biosciences) or FoxP3 Staining Kit (eBioscience)
prior to staining for intracellular antigens. Antibodies against the following antigens were used:
CD11a (clone M17/4; ThermoFisher), CD8a (clone 53-6.7; BD Biosciences or Biolegend or
eBioscience), CD45 (clone 30-F11; Invitrogen or eBioscience), CD45.1 (clone A20; Biolegend),
CD3 (clone eBio500A2; eBioscience), CD45.2 (clone 104; eBioscience), CD90.1 (clone OX-7;
BD Biosciences), CD127 (clone A7R34; eBioscience or clone SB/199; Biolegend), KLRG1
(clone 2F1/KLRG1; Biolegend or eBioscience), CD4 (clone RM4-5; eBioscience or clone
GK1.5; Biolegend), PD-1 (clone RMP1-30; eBioscience), CTLA-4 (clone UC10-4F10-11; BD
Biosciences), NKG2A/C/E (clone 20d5; eBioscience), LAG3 (clone C9B7W; Biolegend), 2B4
(clone m2B4(B6)458.1; Biolegend), CD44 (clone IM7; eBioscience or Biolegend or BD
Biosciences), Gr-1 (clone RB6-8C5; Biolegend), Ly6C (clone HK1.4; Biolegend), Ly6G (clone
1A8; Biolegend), CD11b (M1/70; eBioscience or Biolegend), CD11c (clone N418; Biolegend or
eBioscience), CD169 (clone SER-4; eBioscience), CD115 (clone AFS98; eBioscience), CD64
(clone X54-5/7.1; Biolegend), CCR2 (clone 475301; R&D Systems), CD80 (clone 16-10A1;
Biolegend), MHCII (clone AF6-120.1), F4/80 (clone BM8; Biolegend), Qa-1b (clone
6A8.6F10.1A6; Miltenyi Biotec), PD-L1 (10F.9G2; Biolegend), IDO1 (clone 2E2/IDO1;
Biolegend), IFNγ (clone XMG1.2; Biolegend).
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2.10 Confocal Imaging
Tumor tissue was fixed and processed as previously described.133 Briefly, tumor tissue was fixed
overnight in 0.05M phosphate buffer, 0.1M L-Lysine, 2mg/mL NaIO4, and 10mg/mL
paraformaldehyde. Tissue was dehydrated in 30% sucrose then frozen in OCT (Tissue-Tek).
Tumors were cut into 20µm sections, blocked for two hours in 2% fetal bovine serum, 2% goat
serum, and 0.5% Fc Block before staining for CD169 or F4/80 for 1 hour. Images were acquired
on Zeiss LSM 780 FCS/NLO (Carl Zeeis) or Zeiss LSM 880. Images were analyzed using
Imaris software (Bitplane, Inc.).
2.11 Statistical analysis
Statistical tests were performed in Prism (Graphpad). For tumor growth experiments, tumor
growth curves were compared using two-way repeated measures ANOVA. For other
experiments, a student t-test was used when comparing two groups, and a one-way ANOVA was
used when comparing more than two groups. A paired t-test was used to compare inhibitory
receptor expression in blood and TIL from the same mouse. Survival curves were analyzed
using Logrank test in Prism.
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Chapter 3: Generating MCMV-based Vectors Expressing Multiple
Melanoma Antigens
Abstract:
Tumor antigen-specific CD8+ T lymphocytes can have potent antitumor effects, and evidence
from studies using adoptive cell therapy have shown that sustained antitumor T cell responses
confer the greatest clinical benefit. Thus, generating robust and sustained T cell responses
against tumor antigens is a critical focus of cancer immunotherapy research. Cytomegalovirus is
a herpesvirus that induces dramatic T cell responses against certain viral epitopes that are
sustained at high frequencies over the lifetime of the host, a phenomenon termed “memory
inflation”. Impressively, vaccination with a recombinant murine Cytomegalovirus (MCMV)
expressing an altered melanoma antigen induces a memory inflation T cell response to the
antigen, and this protects mice against a metastatic model of melanoma. In this study, we set out
to engineer a novel recombinant MCMV expressing multiple tumor antigens with the aim of
inducing memory inflation responses against multiple tumor antigens and improving the clinical
efficacy of vaccination. Herein, we show that altering the melanoma antigen Trp2 at one amino
acid reduces the expression of the antigen by recombinant MCMV vectors. We also show, in
contrast to a previously published work, that MCMV expression of the native Trp2 protein does
not delay tumor progression.
Introduction:
With the FDA approval of ipilimumab and nivolumab, cancer immunotherapy has entered
mainstream clinical oncology.58,66 The potency of these therapies in some patients has shown the
immense power of T cells in the fight against cancer. Unfortunately, not all patients respond to
this therapy. T cell infiltration prior to therapy has been correlated with response to checkpoint
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blockade and is a possible marker for stratifying potential responders prior to therapy.134
However, not all patients exhibit this spontaneous antitumor T cell response and thus require
other forms of therapy.
Cancer vaccines have long been a focus of research within the tumor immunology field, but few
vaccines have been effective in human trials.24,45 Our lab previously hypothesized that a
persistent vaccine vector generating a prolonged antitumor T cell response would provide
optimal tumor protection.129,130 Cytomegalovirus generates a unique CD8+ T cell response
termed memory inflation, characterized by the maintenance of a high-frequency of activated,
virus-specific T cells for the lifetime of the host.95 Previously, we showed that a recombinant
murine Cytomegalovirus (MCMV) expressing an altered melanoma antigen, gp100KGP, could
induce a memory inflation CD8+ T cell response against the native gp100 peptide, and
vaccination with this recombinant virus delayed melanoma growth in a metastatic tumor
model.129 Here, we engineer this same vaccine to express a second melanoma antigen, Trp2, and
show that altering Trp2 at one amino acid reduces the expression of the protein in infected cells
in vitro. Surprisingly, vaccination with MCMV vectors expressing both gp100 and Trp2
antigens did not significantly delay tumor growth compared to the MCMV vector expressing the
altered gp100 alone.
Results:
Altering Trp2 limits expression by MCMV-based vectors
Our group has previously generated recombinant MCMV vectors expressing the melanoma
antigen, gp100, or a mutated form of the antigen, gp100KGP. Highlighting the difficulty in
vaccinating against self-peptides, we showed that mice immunized with MCMVgp100 did not
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develop a CD8+ T cell response to gp100. However, mice vaccinated with MCMVgp100KGP
developed a memory inflation T cell response against the native gp100 peptide and were
protected against tumor challenge in a metastatic model of B16F10 melanoma.129 We
hypothesized that the addition of a second melanoma antigen could enhance the efficacy of our
MCMV-based vaccine. To this end, we sought to develop an MCMV vaccine expressing
gp100KGP and a shared melanoma antigen, Trp2, or the mutated protein Trp2-2M. Trp2-2M is
mutated within the CD8+ T cell epitope Trp2180-188 (SVYDFFVWL=>SMYDFFVWL) and has
been shown to generate cross-reactive T cell responses upon peptide vaccination.135 Given the
importance of promoter activity in regulating memory inflation responses and given the effective
antitumor responses seen with MCMVgp100KGP, we aimed to have Trp2 expression controlled
by the same promoter as gp100KGP. To do this, we inserted the native or altered murine Trp2
coding sequence downstream of the gp100KGP coding sequence, separated by an Internal
Ribosomal Entry Site (IRES). This design enables the gp100KGP and the Trp2 genes to be
transcribed into one mRNA transcript under the same promoter. The IRES then allows
translation of Trp2 independent of gp100KGP translation (Figure 3-1).136 Using a two-step galK
positive/negative selection recombineering protocol, we generated two recombinant MCMV
vectors. MCMVgp100KGP-Trp2 was engineered to express the full-length murine Trp2 protein.
MCMVgp100KGP-Trp2-2M was engineered to express a mutated Trp2 protein consisting of a
single amino acid substitution within the CD8+ T cell epitope Trp2180-188
(SVYDFFVWL=>SMYDFFVWL).
We confirmed correct insertion of the IRES-Trp2 construct by sequencing and restriction
mapping of the final bacterial artificial chromosomes (BAC) containing the recombinant MCMV
genomes (Fig. 3-2). We next sought to confirm expression of the melanoma antigens by
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performing Western blots on lysates from infected murine embryonic fibroblasts (MEFs) (Figure
3-3). Trp2 and gp100KGP proteins were not detected in lysates from MEFs infected with WT
MCMV, whereas gp100KGP expression was confirmed in lysates from cells infected with either
recombinant virus. Trp2 was easily detected in lysates from MEFs infected with
MCMVgp100KGP-Trp2; however, there was minimal expression of Trp2-2M in infected MEFs,
suggesting that the 2M mutation may have influenced Trp2 expression or protein stability.
Trp2-specific T cells or antibodies are not detected following vaccination with recombinant
MCMV vectors.
Though it is difficult, several studies have shown it is possible to vaccinate mice with native
Trp2 peptides and elicit a T cell response.137,138 Thus, we decided to test the ability of both
recombinant MCMV viruses to induce CD8+ T cell responses to the native Trp2180-188 epitope.
To this end, mice were vaccinated with 105 PFU WT MCMV, MCMVgp100KGP-Trp2, or
MCMVgp100KGP-Trp2-2M. Seven days after vaccination, splenocytes were stimulated with
native gp10025-33 or native Trp2180-188 peptide for 5 hours and stained for IFNγ expression (Figure
3-4). None of the mice tested showed any reactivity to Trp2, again highlighting the difficulty of
vaccinating against self-antigens. Recently, Xu et al. constructed a MCMV vector expressing
native Trp2 and also could not detect a Trp2-specific T cell response following vaccination.
However, this group showed that vaccination with MCMV expressing Trp2 could generate an
antibody response against Trp2 and slightly delay tumor growth.127 We therefore asked if
MCMVgp100KGP-Trp2 or MCMVgp100KGP-Trp2-2M could also generate tumor-specific
antibodies. To test this, mice were again vaccinated with WT MCMV or recombinant MCMV
and serum was collected 7 days later. An ELISA assay targeting B16F10 tumor lysate was
performed to detect B16-specific antibodies in vaccinated mice. Serum from mice vaccinated
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with WT MCMV showed an increase in reactivity compared to unvaccinated mice, likely a result
of non-specific binding due to increased virus-specific IgG. Serum from mice vaccinated with
either recombinant virus showed similar B16-reactivity compared to WT MCMV, suggesting a
lack of B16-specific IgG in these mice (Figure 3-5). Thus, in contrast to the report by Xu et al.,
we were unable to detect an increase in B16-specific antibodies following vaccination with our
recombinant viruses.
Addition of Trp2 to MCMVgp100KGP does not enhance antitumor response
While we did not detect adaptive immune responses to Trp2 in our previous assays, it was
possible that the addition of Trp2 to MCMVgp100KGP would still yield beneficial antitumor
effects as we were merely failing to detect these cellular responses in our specific assays. We
therefore performed a final set of experiments to determine if addition of Trp2 to
MCMVgp100KGP had any effects on tumor growth. Our previous study utilized a pulmonary
metastatic model of melanoma in which mice were inoculated with B16F10 via the tail vein. In
this model, the melanoma cells seed the lungs, forming individual nodules which can be
quantified. To test the antitumor efficacy of our recombinant MCMV vectors, mice were
inoculated with 105 B16F10 cells via tail vein injection. Three days later, mice were vaccinated
with 105 PFU MCMVgp100KGP, MCMVgp100KGP-Trp2, or MCMVgp100KGP-Trp2-2M.
On day 22, mice were euthanized and pulmonary tumor nodules were counted (Figure 3-6A). As
shown in our previous study, vaccination with MCMVgp100KGP significantly decreased the
tumor burden compared to untreated mice. Similarly, vaccination with MCMVgp100KGP-Trp2
or MCMVgp100KGP-Trp2-2M also significantly reduced the tumor burden compared to
untreated mice. However, tumor burden between vaccinated groups was not significantly
different. Lastly, we confirmed this result in a solid tumor model of melanoma in which B16F10
28

cells are injected intradermally. In this model, a solid tumor mass forms in the skin which can be
measured over time using calipers. To try to increase the sensitivity of detecting differences
between vaccinated groups, mice were vaccinated seven days prior to inoculation with B16
tumors. As in the metastatic model, vaccination with recombinant MCMV vectors delayed
tumor growth when given prophylactically, but the addition of Trp2 did not enhance the efficacy
of MCMVgp100KGP (Figure 3-6B).
Discussion:
The clinical development of vaccines targeting tumor antigens has been largely disappointing,
reducing the optimism of many scientists for this approach to cancer therapy.24 However, the
recent clinical successes of checkpoint inhibitors and adoptive cell therapy have shown the
immense potential of antitumor T cell responses in fighting cancer. Unfortunately, only a subset
of patients respond to these therapies. The effectiveness of these therapies likely depends on
reinvigorating a pre-existing antitumor T cell response, meaning patients without this preexisting response are unlikely to respond.26,134 Therefore, novel methods for generating
antitumor T cell responses in these patients is urgently needed. Vaccination may be one of
several effect means of producing these antitumor T cells, which can then be reinvigorated by
checkpoint inhibition.
With this in mind, our lab has investigated the preclinical utility of Cytomegalovirus-based
vaccines for use in melanoma. CMV infection elicits a unique CD8+ T cell response termed
“memory inflation” which is characterized by the lifelong accumulation of activated virusspecific cells in lymphoid as well as non-lymphoid tissues.95 Impressively, this memory
inflation response is still observed following vaccination with a non-replicative viral vector,
suggesting that vectors with limited virulence could still be used for vaccination.116 A vaccine
29

that could generate such a sustained T cell response against a target antigen could be highly
effective in different settings. Based on this idea, several groups have already tested
recombinant MCMV viruses expressing epitopes from infectious agents like Influenza and
Ebola. In these studies, recombinant MCMV vectors elicit memory inflation CD8+ T cell
responses against the target epitope and provide long-term protection against challenge.119,139
This platform has also shown impressive preclinical results protecting rhesus macaques from
highly pathogenic Simian Immunodeficiency Virus.123-125
Our lab has previously applied this technology to create a novel MCMV-based vaccine
expressing a modified melanoma antigen. By mutating the self-antigen, gp100, within a known
CD8+ T cell epitope, we were able to generate tumor-reactive T cells following vaccination that
delayed tumor progression in a metastatic model of melanoma. However, vaccination was not
curative.129 Antigen loss is a potential escape mechanism for tumors under immune
pressure.140,141 One way to minimize this escape mechanism is to target several antigens. At the
same time, polyclonal T cell responses are likely to be more effective in initial therapy as well.
For these reasons, we sought to develop an MCMV-based vaccine expressing multiple
melanoma antigens.
In this study, we engineered our original MCMV melanoma vaccine (MCMVgp100KGP) to
express a second melanoma antigen, Trp2, generating MCMVgp100KGP-Trp2. Because it is
difficult to vaccinate against self-proteins, we also developed a second virus expressing a
modified Trp2, MCMVgp100KGP-Trp2-2M. We hypothesized that this second modification
would break self-tolerance and stimulate CD8+ T cells recognizing the Trp2180-188 epitope.135
While MCMVgp100KGP-Trp2 expressed high levels of gp100 and Trp2 in vitro,
MCMVgp100KGP-Trp2-2M showed dramatically reduced expression of Trp2 at the protein
30

level. The previous study using Trp2-2M vaccination utilized synthesized peptides and therefore
did not investigate the effects of the 2M alteration on Trp2 protein expression.135
MCMVgp100KGP-Trp2 and MCMVgp100KGP-Trp2-2M differ only at one amino acid within
the protein coding region. Thus, the regulatory units influences Trp2 transcription should remain
functional between our two vectors. It is more likely that the 2M modification influences either
the translation or protein stability of Trp2. These results highlight the potential problems in
engineering altered epitopes into full-length proteins within expression vectors. Engineering
MCMV vectors expressing shorter peptides containing the epitopes of interest may improve
epitope expression by reducing potential misfolding.
Previous reports have shown that potent vaccine formulations can induce T cell responses
against the native Trp2 peptide.137,138 We therefore decided to test our novel MCMV vectors in
vivo. We were unable to detect Trp2-specific CD8+ T cell responses following vaccination with
either recombinant MCMV, illustrating the difficulty of vaccinating against self-proteins. A
previous study by Xu et al. similarly showed that a MCMV vector expressing the native Trp2
was unable to induce a Trp2-specific T cell response following vaccination. However, this study
showed that vaccination with this vector slightly protected mice from tumor challenge by
eliciting a Trp2-specific antibodies.127 We were unable to detect tumor-specific IgG following
vaccination with MCMVgp100KGP-Trp2, and vaccination with either MCMVgp100KGP-Trp2
or MCMVgp100KGP-Trp2-2M did not delay tumor growth compared to MCMVgp100KGP in a
solid tumor or metastatic model of B16 melanoma.
Our results stand in stark contrast to the study by Xu et al. While neither study could generate
Trp2-reactive T cells, we were unable to show any clinical benefit of Trp2 expression by an
MCMV vector. Several differences in our studies may explain this, the discrepancy. First, the
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regulatory elements controlling Trp2 were different in the two studies. Xu et al. inserted the
complete Trp2 coding sequence under the control of the human CMV major immediate early
promoter and enhancer element, whereas, in our study, Trp2 transcription was controlled by the
human CMV immediate early promoter without enhancer element.127 As described above, this
ensured that in our study Trp2 was transcribed along with gp100KGP but was translated
independent of gp100KGP through an internal ribosomal entry site. Our data show that Trp2
was successfully expressed in MEFs infected with MCMVgp100KGP-Trp2. Nonetheless, the
different regulatory elements involved in these two studies may influence the overall expression
levels of Trp2 or the cell-specific expression of Trp2. Differences in the overall expression of
Trp2 or cell-specific expression may account for the differences observed in the two studies.
Second, discrepancies in inoculation dose may contribute to our conflicting results. Xu et al.
vaccinated mice with 4x106 PFU MCMV-TRP2 which is a large inoculation dose for MCMV.127
In our current study, mice were vaccinated with 105 PFU MCMVgp100KGP-Trp2. Inoculation
dose is known to impact the magnitude of antibody responses to MCMV antigens.142 While this
lower dose was effective enough to delay tumor growth compared to untreated mice, we did not
observe an IgG response to B16 or enhanced tumor protection compared to MCMVgp100KGP
vaccination.
In conclusion, in this study we set out to generate a recombinant MCMV vaccine expressing
multiple melanoma antigens with the aim of generating multiple CD8+ T cell memory inflation
responses against melanoma. Herein, we show that the addition of native Trp2 to MCMV
vectors is unable to break self-tolerance. We were unable to detect T cell or antibody responses
to Trp2 following vaccination with MCMVgp100KGP-Trp2. In order to break self-tolerance
against Trp2, we created a second MCMV vector expressing an altered Trp2. However,
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mutating Trp2 within the CD8+ T cell epitope Trp2180-188 significantly reduced the expression of
the full-length protein in infected MEFs. This study highlights the difficulty in vaccinating
against shared tumor antigens. Overcoming tolerance mechanisms is a problematic step in
vaccinating against shared tumor antigens. Future studies generating MCMV-based vaccines
against tumor-specific epitopes, so called neo-epitopes, may enhance the efficacy of this vaccine
platform in tumor immunotherapy.

Figures:

Figure 3-1: Expression of gp100KGP and Trp2 in MCMV vectors. In order to keep Trp2
under an effective memory inflation promoter, the Trp2 coding sequence was inserted
downstream of gp100KGP before the poly(A) signal sequence and separated by an internal
ribosomal entry site (IRES). This allows gp100KGP and Trp2 transcription under the HCMV
promoter into a single mRNA transcript. Translation of Trp2 will occur independent of
gp100KGP due to IRES recruitment of ribosomal machinery.
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Figure 3-2: Restriction map of bacterial artificial chromosomes containing recombinant
MCMV genomes. BAC DNA encoding (A) MCMVgp100KGP, (B) MCMVgp100KGP-Trp2,
or (C) MCMVgp100-Trp2-2M were purified and digested with HindIII for 4 hours and run on
0.6% agarose gel for 24 hours. Arrows show the expected changes in restriction bands following
correct insertion of the IRES-Trp2 sequences.
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Figure 3-3: Expression of melanoma antigens in fibroblasts infected with recombinant
MCMV vectors. Mouse embryonic fibroblasts (MEFs) were infected with recombinant MCMV
vectors and lysates were analyzed by Western blot for protein expression of gp100 or Trp2.
Lysates from 1) uninfected MEFs or 2) MEFs infected with WT MCMV showed no Trp2 or
gp100 expression. Lysates from 3) MEFs infected with MCMVgp100KGP-Trp2 showed clear
bands for Trp2 and gp100, whereas lysates from 4) MEFs infected with MCMVgp100KGPTrp2-2M showed clear gp100 expression but minimal Trp2 expression. Band specificity was
confirmed using lysates from 5) B16F10 cells in culture.
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Figure 3-4: Trp2-specific T cells are not detected following vaccination with recombinant
MCMV vectors. C57BL/6 mice were vaccinated with 105 PFU WT MCMV,
MCMVgp100KGP, MCMVgp100KGP-Trp2, or MCMVgp100KGP-Trp2-2M i.p. Seven days
later, splenocytes were stimulated with m38 peptide (SSPPMFRV), gp100 peptide
(EGSRNQDWL), Trp2 peptide (SVYDFFVWL), or PMA/I for 5 hours followed by intracellular
cytokine staining. Representative plots of 3 mice/group gated on CD45+CD3+CD8+ cells.
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Figure 3-5: B16-specific antibodies are not detected following vaccination with
recombinant MCMV vectors. Serum was collected from mice that were previously vaccinated
7 days prior with WT or recombinant MCMV. Serum was serially diluted and incubated on
plates pre-coated with B16 tumor lysate. Plates were washed and stained with anti-mouse IgGHRP and incubated with TMB substrate prior to absorbance reading at 492 nm. Serum from
mice infected with WT MCMV or recombinant MCMV all showed increased absorption
compared to serum from uninfected mice. However, there was no significant difference in
absorption between the different MCMV viruses. n=3 mice/group.
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Figure 3-6: Addition of Trp2 to MCMVgp100KGP does not improve antitumor response
vs. MCMVgp100KGP. A) Mice were inoculated with 105 B16F10 via tail vein injection and
vaccinated with 105 PFU recombinant MCMV three days later. On Day 22, mice were sacrificed
and lung tumor nodules were counted. B) Mice were vaccinated with 105 PFU recombinant
MCMV seven days prior to intradermal inoculation with 105 B16F10. Tumor surface area was
monitored over time using manual calipers. n=7-8 mice/group for A) and 10-16 mice/group for
B). *p<0.05; **p<0.01.
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Chapter 4: Combination Immunotherapy with MCMV-based
Vaccines

Abstract:
With the exception of cancers associated with infectious agents, cancer vaccines have largely
failed to impact disease progression. The reasons for this are multifactorial, including
suboptimal vaccine formulations, poor choice of target antigens, and a highly
immunosuppressive tumor microenvironment. In this study, we sought to increase the antitumor
effects of a MCMV-based tumor vaccines by combining vaccination with other clinicallyrelevant immunotherapies to enhance antitumor T cell responses within the tumor
microenvironment. Herein, we show that vaccination against a foreign tumor antigen can
significantly delay tumor growth, and increasing the magnitude of this response through adoptive
cell therapy cures mice with established tumors. In contrast, vaccination against a shared tumor
antigen is insufficient to delay growth of an established solid tumor. Increasing the frequency of
the antitumor T cell response through adoptive cell therapy significantly delays tumor growth,
but vaccination also induces a robust counter-regulatory response marked by elevated PD-L1,
Qa-1b, IDO expression, and recruitment of monocytic MDSCs. Surprisingly, combination
immunotherapy targeting several of these pathways did not impact survival of tumor-bearing
mice. Thus, this study highlights several potential barriers to effective tumor vaccination when
targeting a shared tumor antigen and questions the accuracy of inhibitory pathway expression as
a biomarker for responses to therapy.
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Introduction:
After decades of research, immunotherapy has finally joined surgery, radiotherapy, and
chemotherapy as a standard treatment modality in clinical oncology.58,59,66 Unfortunately, these
therapies seem to only work in patients who have a pre-existing immune response against the
tumor, so called “inflamed” tumors, leaving little to no benefit for patients with “non-inflamed”
tumors.143 Methods for converting “non-inflamed” tumor into “inflamed” ones are therefore
needed to treat this subset of patients. Vaccination is one potential method to generate an
adaptive immune response against tumor cells. Vaccination against tumor antigen has been a
highly active area of research for decades that has yielded little clinical benefit as
monotherapy.23,24 Reasons for the failures likely include choice target antigen and an
immunosuppressive tumor microenvironment.
Recent studies have suggested that the clinical responses seen in some patients following T cell
checkpoint blockade or adoptive cell therapy are likely due to T cell responses against mutated
tumor peptides termed neo-epitopes.39-42,78 Because they target non-self-peptides, high affinity
neo-epitope-specific T cells do not get deleted during development in the thymus and are likely
more effective in recognizing tumor cells. Several groups have shown in preclinical models that
it is possible to vaccinate against neo-epitopes and delay tumor growth, and clinical trials
vaccinating patients against these antigens are currently underway (NCT01970358;
NCT02035956).34-36
The majority of tumor vaccines tested thus far have targeted shared antigens, i.e. antigens
expressed by malignant and healthy tissue alike.24 Vaccination against this class of tumor
antigen is difficult because high affinity T cells recognizing these antigens are largely deleted in
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the thymus during development or are rendered unresponsive due to peripheral tolerance.
However, it is possible to stimulate T cells against these antigens in certain cases.43
Studies focused on a particular form of immunotherapy called adoptive cell therapy have
suggested that prolonged T cell responses against tumor antigen inversely correlate with clinical
progression.48 Our lab has previously hypothesized that a persistent vaccine stimulating lifelong
T cell responses against tumor antigen would be an effective cancer immunotherapy.129,130 To
test this, our group developed a vaccine based on Murine Cytomegalovirus targeting a shared
melanoma antigen, gp100. By mutating gp100 within a CD8+ T cell epitope, we were able to
generate gp100-reactive T cells which delayed metastatic tumor progression following
vaccination with MCMVgp100KGP. However, vaccinated mice eventually succumb to
disease.129 In the current study, we tested whether MCMV-based vaccines were effective in a
solid tumor model (as opposed to the pulmonary metastatic model previously described). In this
way, we could examine the influence of an established tumor microenvironment on vaccinestimulated T cells. Our results show that an MCMV-based vaccine targeting a model neoepitope is highly effective in treating melanoma-expressing the same neo-epitope, and combining
this vaccination with adoptive cell therapy completely cures mice of disease. We also show that
prophylactic vaccination with MCMVgp100KGP delays tumor growth, but therapeutic
vaccination has no effect on growth of established tumors. Combining MCMVgp100KGP
vaccination with adoptive cell therapy delays growth of established tumors and also induces
several counter-regulatory mechanisms, including expression of inhibitory receptor ligands and
recruitment of immunoregulatory cells. Surprisingly, combination immunotherapy targeting
several of these counter-regulatory pathways did not enhance the efficacy of vaccination. This
study highlights the difficulty in treating a highly immunosuppressive tumor with a vaccine
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targeting a shared antigen and suggests that expression of immunosuppressive molecules within
the tumor microenvironment does not always predict response to some modes of
immunotherapy.
Results:
Therapeutic vaccination with MCMVgp100KGP does not delay tumor growth in an intradermal
solid tumor model.
Our group has previously shown that MCMVgp100KGP vaccination reduces tumor burden in a
pulmonary metastatic model of B16 melanoma.129 In order to more closely examine the impact
of the tumor microenvironment on vaccine efficacy, we switched to an intradermal solid tumor
model in which a single solid tumor forms rather than multiple pulmonary nodules, allowing us
to track tumor growth over time and easily isolate tumor infiltrating leukocytes (TIL). To test
the efficacy of vaccination in this model, female C57BL/6 mice were vaccinated with 105 PFU
MCMVgp100KGP or mock vaccinated seven days prior to intradermal challenge with 105
B16F10 melanoma cells. As expected, vaccinated mice were protected from tumor challenge,
showing significantly delayed tumor growth (Figure 4-1A). In contrast, therapeutic vaccination
three days following tumor challenge had minimal effect on tumor growth (Figure 4-1B). This
suggested that an established tumor microenvironment may severely limit the efficacy of
vaccine-stimulated T cells. There are several mechanisms that may explain this limitation, one
of which is that vaccine-stimulated T cells fail to migrate into the tumor parenchyma. To test
this idea, mice were inoculated with B16F10 i.d. and vaccinated three days later. Tumors were
harvested and TIL isolated for flow cytometry. Vaccinated mice had significantly more CD8+
TIL than unvaccinated mice, and CD8+ TIL expressed higher levels of the activation marker,
CD11a in vaccinated mice vs. mock vaccinated (Figure 4-2A&B). Though some of the CD8+
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TIL in vaccinated mice are likely MCMV-specific and not gp100-specific, this data nonetheless
shows that MCMV-stimulated T cells can infiltrate a solid tumor, suggesting lack of T cell
migration is unlikely to account for therapeutic inefficiency.
PD-1 and CTLA-4 blockade do not improve antitumor response of therapeutic MCMVgp100KGP
Immune checkpoint inhibitors against PD-1 and CTLA-4 have recently been approved for use in
metastatic melanoma.58,66 PD-1 and CTLA-4 are inhibitory receptors expressed on the surface of
activated T cells that limit T cell activation. We asked whether TIL from MCMVgp100KGP
vaccinated mice expressed these inhibitory receptors. Around 50% of CD8+ TIL expressed PD1, regardless of whether mice received vaccination, while only 5% of CD8+ TIL expressed
CTLA-4 (Figure 4-2C-F). A previous study showed that PD-1 or CTLA-4 blockade could
synergize with vaccination to B16 melanoma when given early in tumor progression.144 We
therefore asked if checkpoint blockade could synergize with MCMVgp100KGP vaccination. To
this end, mice were inoculated with B16F10 i.d. and vaccinated with MCMVgp100KGP or mock
vaccinated. Mice either received anti-PD-1 on days 6, 9, and 12 (Figure 4-3B) or anti-CTLA-4
on days 3, 6, and 9 (Figure 4-3C). Neither therapy significantly delayed tumor growth compared
to unvaccinated mice.
Adoptive cell therapy targeting model neo-epitope enhances MCMVova vaccination
Adoptive cell therapy is a form of immunotherapy that involves transferring high frequencies of
ex vivo cultured tumor-reactive T cells into patients. These tumor-reactive T cells are either
isolated directly from tumor tissue and expanded in culture before transfer, or peripheral blood
lymphocytes are genetically engineered to express a tumor-specific receptor.49 Importantly,
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clinical response has been correlated with persistence of transferred cells in the patient, sparking
a wave of interest in extending transferred cell survival.48 Several groups have tried to take
advantage of the persistent nature of the T cell response to CMV to extend the survival of tumorreactive T cells. Most of these efforts have focused on redirecting CMV-specific inflationary T
cells to recognize tumor antigen.145-147 In a similar way, we hypothesized that CMV-based
vaccines would promote persistence of adoptively transferred tumor-reactive T cells. To test
this, we first utilized a recombinant MCMV expressing the model antigen, ovalbumin
(MCMVova). MCMVova infection induces a robust inflationary T cell response that protects
mice from challenge with B16 tumor cells expressing ova.129 We first asked if MCMVova could
promote long-term persistence of adoptively transferred T cells. C56BL/6 mice received 105
OT-I T cells i.v., which express a transgenic T cell receptor recognizing SIINFEKL epitope
within ovalbumin, followed by vaccination with 105 PFU WT MCMV or MCMVova. As
expected, OT-I cells expanded dramatically in response to MCMVova vaccination but were
undetectable in mice vaccinated with WT MCMV (Figure 4-4A). OT-I expansion peaked seven
days after transfer and displayed a typical effector memory phenotype characterized as KLRG1+
CD127lo (Figure 4-4B). OT-I frequency progressively declined in 8/9 mice, while in one mouse,
OT-I cells were maintained at high frequency over four months after transfer (Figure 4-4C).
Our lab has previously shown that MCMVova delays tumor growth and improves survival in a
metastatic model of melanoma.129 We hypothesized that adoptive cell therapy could synergize
with MCMV-based vaccines to delay tumor growth. Mice were inoculated with B16ova i.d. and
eight days later received 105 OT-I cells i.v. followed by vaccination with WT MCMV or
MCMVova. Like in the metastatic model, MCMVova significantly delayed growth of an
intradermal solid tumor, yet mice eventually succumbed to disease. Adoptive cell transfer and
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MCMVova vaccination significantly improved therapeutic efficacy and cured several mice
(Figure 4-5). This data shows that adoptive cell therapy can synergize with a persistent vaccine
vector to cure mice, even if transferred cells do not persist long-term. This may be a result of the
dramatic expansion of OT-I cells early followed by the persistent endogenous OVA-specific
response generated by MCMVova or the continued presence of endogenous OVA-specific T
cells stimulated by MCMVova.
MCMVgp100KGP is a more potent stimulatory of adoptively transferred gp100-specific T cells
than VSVgp100KGP
Given the dramatic results seen when combining adoptive cell therapy and MCMV vaccines
targeting foreign antigens, we next asked whether this combination therapy would be as effective
when targeting a shared tumor antigen. For this, we utilized transgenic T cells (PMEL)
expressing a T cell receptor recognizing the CD8+ T cell epitope gp10025-33.148 We began by
asking whether MCMVgp100KGP could stimulate adoptively transferred PMEL cells. C57BL/6
mice received 105 CD8+ PMEL cells i.v. followed by vaccination with PBS, WT MCMV,
MCMV expressing native murine gp100 (MCMVgp100), or MCMVgp100KGP. Five days later,
only mice vaccinated with MCMVgp100KGP showed expansion of transferred PMELs (Figure
4-6A). Similar to the OT-I and MCMVova response, PMEL cells were not maintained long-term
in the blood of mice vaccinated with MCMVgp100KGP (Figure 4-6B). We next asked how
MCMVgp100KGP stimulation compared to an acute viral vector, Vesicular Stomatitis Virus
expressing gp100KGP (VSVgp100KGP). Mice received 105 PMEL cells i.v. followed by
vaccination with PBS, MCMVgp100KGP, or VSVgp100KGP. Five days later, mice vaccinated
with MCMVgp100KGP displayed a higher frequency of PMEL cells in blood compared to mice
vaccinated with VSVgp100KGP. This difference was also seen in peripheral blood and lungs
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five (blood) and eight (lungs) months after vaccination (Figure 4-6C & Figure 4-7). Thus, while
MCMVgp100KGP did not sustain a very high frequency of PMEL cells after transfer, it
generates more potent T cell responses compared to an acute viral vector.
Adoptive cell therapy and MCMVgp100KGP vaccination significantly delays growth of
established solid tumors
As discussed above, prophylactic vaccination with MCMVgp100KGP significantly delays B16
tumor growth, but therapeutic vaccination does not influence tumor growth. In contrast, we
found that vaccination with MCMVova potently delayed B16ova tumor growth. This
discrepancy may be partly attributed to the nature of the target antigen. Because ova is a foreign
antigen, high affinity T cells recognizing ova should not be hindered by central and peripheral
tolerance mechanisms. However, gp100 is a shared tumor antigen expressed in B16 melanoma
as well as normal melanocytes. Because of this, high affinity T cells recognizing gp10025-33 are
deleted in the thymus during development. Thus, any vaccine targeting gp100 is severely limited
by a low precursor frequency. We therefore hypothesized that increasing the precursor
frequency of gp100-reactive T cells would enhance the effect of MCMVgp100KGP vaccination.
As expected, combining MCMVgp100KGP vaccination with adoptive transfer of PMEL cells
significantly delayed growth of established tumors, while either monotherapy had no effect on
tumor growth (Figure 4-8). Thus, like our results using MCMVova, adoptive cell therapy greatly
enhances the efficacy of MCMV-based vaccines even though adoptively transferred cells do not
persist at high frequency.
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The tumor microenvironment induces the expression of several inhibitory receptors on the
surface of MCMVgp100KGP-stimulated T cells
Though tumor growth was delayed with adoptive cell therapy and vaccination, tumors continued
to progress even with therapy. We asked what factors may limit the efficacy of this therapy.
The tumor microenvironment can greatly influence immune cell function.149,150 We first asked
whether MCMVgp100KGP-stimulated T cells were influenced by the tumor microenvironment.
To test this, tumor-bearing mice were treated with PMEL transfer and MCMVgp100KGP
vaccination, and six days later, peripheral blood and tumor tissue were harvested for analysis by
flow cytometry. At this time point, PMEL cells made up 5-10% of CD8+ T cells from peripheral
blood but constituted up to 50% of CD8+ T cells in tumor tissue, suggesting a preferential
accumulation of these cells within the tumor tissue (data not shown). PMEL cells isolated from
tumor tissue expressed significantly more PD-1, LAG-3, 2B4, and NKG2A/C/E compared to
PMEL cells isolated from peripheral blood (Figure 4-9). PD-1, LAG3, and 2B4 are inhibitory
receptors upregulated on exhausted T cells. Expression of several of these receptors on T cells is
associated with reduced effector function in exhausted T cells.151 Thus, our data suggests that
the tumor microenvironment alters the functionality of PMEL cells and may limit the efficacy of
out therapy.
Inhibitory ligands are upregulated on tumor cells and tumor infiltrating leukocytes after
vaccination with MCMVgp100KGP
PD-1 binds its cognate ligand PD-L1 within the tumor microenvironment to limit T cell
function.77 PD-L1 is upregulated in response to IFNγ, but it can also be constitutively expressed
in some cancers.152 PD-L1 expression has also been postulated as a predictive marker for
response to anti-PD-1 therapy.76,152 NKG2A is an inhibitory receptor expressed on the surface of
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NK cells and CD8+ T cells. NKG2A binding its cognate ligand, HLA-E in humans and Qa-1b in
mice, limits CD8+ T cell function during infection and protects tumor cells from cytolysis.153,154
Because PMEL cells within the tumor tissue expressed high levels of PD-1 and NKG2A, we next
asked if PD-L1 and Qa-1b are also expressed in the tumor microenvironment. To this end, mice
were inoculated with B16F10 expressing red fluorescent protein (B16RFP) and left untreated,
treated with PMEL transfer and WT MCMV vaccination, or treated with PMEL transfer and
MCMVgp100KGP vaccination. Six days later, tumor tissue was harvested for flow cytometry.
Only 2% of B16RFP cells from culture expressed PD-L1 and less than 2% expressed Qa-1b
(Figure 4-10A-C). 20-50% of RFP+ cells from untreated tumors and control treated tumors were
PD-L1+ and about 5-20% were PD-L1+ and Qa-1b+. In contrast, PMEL transfer and
MCMVgp100KGP induced significant upregulation of PD-L1 and Qa-1b on RFP+ tumor cells
(Figure 4-10A-C). Essentially all tumor cells expressed PD-L1 and 50-60% of tumor cells
expressed both PD-L1 and Qa-1b. Similarly, both inhibitory ligands were also upregulated on
CD45+CD8- tumor infiltrating leukocytes following MCMVgp100KGP vaccination (Figure 410D-F). This data highlights the highly dynamic nature of inhibitory ligand expression within
the tumor microenvironment and shows that infiltration by tumor non-specific T cells (i.e. virus
specific T cells following WT MCMV) does not induce a counter-regulatory response.
Combination checkpoint blockade does not extend survival following MCMVgp100KGP
vaccination
Antibodies targeting PD-1 and PD-L1 are now approved therapies for metastatic melanoma.66
Blocking antibodies against NKG2A are also in development for the treatment of cancer.155
Given the high expression of these inhibitory pathways following MCMVgp100KGP
vaccination, we hypothesized that these counter-regulatory pathways limit T cell function within
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the tumor microenvironment. We therefore asked if blockade of PD-1 and Qa-1b could
synergize with MCMVgp100KGP vaccination to delay tumor growth. Mice were inoculated
with B16F10 and five days later were left untreated or received PMEL transfer and
MCMVgp100KGP vaccination. On days 10, 12, and 14, mice were treated with anti-PD-1
and/or anti-Qa-1b and tumor growth measured every two to three days. Anti-PD-1 therapy had a
minor effect on survival, but neither anti-PD1, anti-Qa-1b, nor combination blockade
significantly prolonged survival of vaccinated mice (Figure 4-11).
MCMVgp100KGP vaccination induces accumulation of monocytic MDSCs and upregulation of
IDO1
Several studies have reported the induction of other immunosuppressive mechanisms in response
to antitumor T cell activity.72,156 We therefore asked if MCMVgp100KGP vaccination increased
the recruitment of other immunosuppressive cells to the tumor microenvironment. To this end,
mice were inoculated with B16F10 i.d. and left untreated, treated with PMEL transfer and WT
MCMV vaccination, or treated with PMEL transfer and MCMVgp100KGP vaccination. As
expected, Thy1.1+ PMEL cells accumulated in tumor tissue in mice vaccinated with
MCMVgp100KGP but not WT MCMV (Figure 4-12A). In response to MCMVgp100KGP
vaccination, we noted an impressive accumulation of Gr-1+CD11b+ myeloid cells which was not
noted by PMEL transfer and vaccination with control viruses WT MCMV or MCMVgp100
(Figure 4-12B). Gr-1+ cells within the tumor microenvironment are generally characterized as
Myeloid Derived Suppressor Cells (MDSCs). The Gr-1 antibody recognizes both Ly6G and
Ly6C on MDSCs, and therefore, labels two populations of MDSCs: monocytic-MDSCs
characterized by Ly6C expression and granulocytic-MDSCs characterized by Ly6G
expression.157 B16F10 tumors contained few Ly6G+ cells regardless of vaccination status
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(Figure 4-12D). In contrast, Ly6C+ myeloid cells greatly outnumbered Ly6G+ cells in all tumors
and significantly increased in number following MCMVgp100KGP vaccination (Figure 4-12C).
A previous study showed that adoptive transfer of in vitro activated PMEL cells induced a
counter-regulatory recruitment of Ly6C+ MDSCs that potently inhibited T cell responses.156 We
hypothesize that our results show an accumulation of these same previously described MDSCs.
Indoleamine 2,3-dioxygenase 1 (IDO) is a cytosolic enzyme responsible for the degradation of
tryptophan, and its expression is regulated by IFNγ.72,158 IDO is expressed in myeloid cells as
well as tumor cells and has been shown to limit the response to checkpoint blockade.159-161 A
recent study also showed that IDO expression by B16 melanoma resulted in the recruitment of
monocytic-MDSCs within the tumor microenvironment.162 Given the significant accumulation
of Ly6C+ myeloid cells in response to MCMVgp100KGP and the responsiveness of IDO to
IFNγ, we hypothesized that MCMVgp100KGP would also upregulate IDO expression within the
tumor and this upregulation may be partly responsible for the accumulation of Ly6C+ cells
following MCMVgp100KGP vaccination. As before, mice were inoculated with B16RFP i.d.
and left untreated, treated with PMEL transfer and WT MCMV vaccination, or treated with
PMEL transfer and MCMVgp100KGP vaccination. Six days after treatment, IDO expression
was trending upwards in RFP+ tumor cells from mice treated with MCMVgp100KGP
vaccination but failed to reach statistical significance (Figure 4-13). Thus, in addition to PD-L1,
tumor cells also appeared to upregulate IDO (albeit at low levels) in response to antitumor T cell
attack following MCMVgp100KGP vaccination.
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Combination IDO inhibition and checkpoint blockade does not improve response to
MCMVgp100KGP vaccination
As stated above, IDO has been shown to inhibit antitumor T cell responses and diminish
therapeutic responses to checkpoint blockade.161,163 Several inhibitors of IDO1 are entering
clinical trials, including 1-methyl-tryptophan (1-MT).164 Given the enhanced expression of both
PD-L1 and IDO in response to MCMVgp100KGP vaccination, we hypothesized that inhibition
of these pathways would improve therapeutic responses to MCMVgp100KGP. To test this, mice
were inoculated with B16F10 i.d. and treated with PMEL transfer and MCMVgp100KGP
vaccination five days later. Starting on day 7, mice received 1-MT in their drinking water or
control water. Mice were also treated with anti-PD-1 blocking antibody; however, combination
therapy did not influence tumor growth and did not extend survival of mice following
vaccination (Figure 4-14).
Combination chemo-immunotherapy delays tumor growth and prolongs survival of mice bearing
established tumors
Studies have shown that host preconditioning with chemotherapy or radiation can significantly
enhance the effects of immunotherapy.165 Cyclophosphamide (CTX) is a commonly used
alkylating agent that can synergize with immunotherapy. At low doses, CTX can reduce
numbers of immunosuppressive Tregs, and at high doses, it can modulate type I IFN signaling to
enhance vaccination.166-168 We therefore asked if MCMVgp100KGP vaccination in combination
with cyclophosphamide preconditioning could treat established tumors. To test this, mice were
challenged with B16F10 and six days later received a single 4mg dose of CTX. The following
day mice were treated with 105 in vitro activated PMEL cells, vaccination with
MCMVgp100KGP, or both (Figure 4-15A). CTX alone significantly delayed tumor growth
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compared to untreated mice (Figure 4-15B). MCMVgp100KGP vaccination alone, PMEL
transfer alone, or PMEL transfer and WT MCMV vaccination did not delay tumor growth
compared to CTX alone. However, PMEL transfer and MCMVgp100KGP vaccination
significantly delayed tumor growth compared to all other treatment groups. Combination
therapy also significantly prolonged survival, suggesting that combination therapy combining
several therapeutic modalities may be most beneficial in delaying tumor growth (Figure 4-15C).
Discussion:
With the FDA approval of ipilimumab and nivolumab, cancer immunotherapy has finally
become a standard treatment modality for some cancers. Unfortunately, not all patients respond
to these therapies. Increasing evidence suggests that response is often seen in patients with
tumors containing a high frequency of nonsynonymous mutations and high levels of T cell
infiltration.41,42,73,77,134 These observations have led scientists and clinicians to distinguish
tumors as “inflamed” i.e. containing many T cells or “non-inflamed” in which tumors-specific T
cells are lacking.134,143 “Inflamed” tumors contain spontaneous T cell responses recognizing
tumor antigen, yet these T cells are prevented from destroying malignant cells. Patients with
these kinds of tumors are more likely to benefit from checkpoint blockade than patients with
“non-inflamed” tumors. Therefore, novel methods for converting “non-inflamed” tumors into
“inflamed” tumors are highly sought. A potential method to do this is through vaccination
against tumor antigen.
Cytomegalovirus is a β-herpes virus that infects most individuals over the age of 40.80 This
persistent infection induces a substantial expansion of CD8+ T cells recognizing viral antigens,
and these T cells are maintained at high frequency over the lifetime of the host.95 Our lab has
previously shown that a persistent vaccine vector based on murine Cytomegalovirus generates
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prolonged T cell responses against the melanoma antigen, gp100 and protects mice from a model
of metastatic melanoma.129 However, mice eventually succumb to disease.
In this study, we sought to determine if our vaccine MCMVgp100KGP would be effective
against a solid intradermal tumor. As hypothesized, prophylactic MCMVgp100KGP vaccination
protected mice from an intradermal challenge of B16F10 melanoma. However, therapeutic
vaccination had no effect on tumor growth. This inefficiency was not due to T cell exclusion
from the tumor microenvironment as MCMVgp100KGP vaccination significantly increased the
number of CD8+ T cells within the tumor.
Adoptive cell therapy is an effective form of immunotherapy involving the transfer of large
numbers of ex vivo cultured tumor-reactive T cells into patients. One version of this therapy
involves genetically engineering T cells to express tumor-specific receptors.26 Because most
self-reactive T cells are deleted in the thymus during development, this form of therapy avoids
the problem of vaccinating against self-antigens. In this study, we asked whether
MCMVgp100KGP was limited by the low precursor frequency of gp100-specific T cells. Our
previous results showed that about 2% of CD8+ T cells recognized gp100 following
MCMVgp100KGP vaccination.129 Here, we show that following MCMVgp100KGP
vaccination, PMEL cells made up 10-20% of circulating CD8+ T cells. This increase in
magnitude significantly delayed tumor growth, confirming our hypothesis that
MCMVgp100KGP vaccination is limited by precursor frequency.
Work within the field of adoptive cell therapy has shown that persistence of transferred cells
correlates with clinical efficacy.48 Therefore, significant research is focused on identifying
methods to improve the persistence of adoptively transferred cells. Several groups have tried to
utilize the persistent and ubiquitous nature of Cytomegalovirus to maintain adoptively
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transferred cells.146,147 These studies have genetically engineered CMV-specific T cells to
express a tumor-specific receptor with the thought that continuous stimulation through the
endogenous CMV-specific TCR would maintain transferred cells long-term. In this same line of
thought, we hypothesized that a CMV-based vaccine could maintain adoptively transferred T
cells long-term by continuously stimulating the expansion of these cells. We tested this in two
models. MCMVova vaccination induced a massive expansion of adoptively transferred OT-I
cells, but these cells were not maintained long-term. Only one of nine mice showed a substantial
maintenance of OT-I’s in peripheral blood several months after vaccination. This is in contrast
to a previous study by Turula et al. showing that infection with MCMVova maintained
transferred OT-I’s at high frequency over time.169 This report also noted immune rejection of
transferred OT-I’s in some mice due to minor allelic changes between mouse strains. Though
unlikely, this same rejection may account for the reduced persistence of OT-I’s in our study as
well. Another possible reason for this discrepancy is the number of transferred cells. In the
study by Turula et al., mice received 600 OT-I cells prior to infection, whereas our study
involved the transfer of 105 OT-I cells.169 This difference in starting cell number may influence
persistence of cells through clonal competition or reduction in viral load, which is known to
influence MCMV T cell inflation.170 In a second model, we show that MCMVgp100KGP
maintains transferred PMEL cells at higher frequencies than VSVgp100KGP, albeit still only at
1% of total CD8+ T cells in peripheral blood. PMEL cells were found at slightly higher
frequencies in lungs of mice vaccinated with MCMVgp100KGP 263 days prior. Thus, similar to
MCMVova, MCMVgp100KGP maintains transferred antitumor T cells but at low frequency.
Impressively, despite the decline in frequency of transferred cells over time, OT-I transfer and
MCMVova vaccination cured several mice of B16ova, and PMEL transfer and
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MCMVgp100KGP vaccination significantly delayed growth of B16F10 tumors. These results
highlight the potential of MCMV-based vaccines in combination with adoptive cell transfer and
emphasize the difficulty in targeting a non-mutated shared tumor antigen.
While adoptive transfer and MCMVgp100KGP vaccination delayed B16 tumor growth, mice
eventually succumb to disease. Many mechanisms exist that allow malignant cells to evade host
immunity, and several of these pathways are highly upregulated in response to T cell attack, a
process termed adaptive resistance.171 In response to T cell attack, “inflamed” tumors will
upregulate counter-regulatory mechanisms like PD-L1 expression, IDO1 expression, and
recruitment of regulatory immune cells.72 As stated above, patients who respond to current
immunotherapies tend to show increased T cell infiltration within the tumor tissue and
expression of these counter-regulatory pathways, suggesting an active immune response.
B16F10 is notoriously difficult to treat with single agent immunotherapy and is characterized by
low levels of immune cell infiltration relative to other murine tumors.163,172,173 We would
therefore classify B16F10 as a “non-inflamed” tumor. As discussed above, “non-inflamed”
tumors are thought to be unresponsive to single agent immunotherapy due to lack of T cell
infiltration within the tumor tissue. In this study, we show that following PMEL transfer and
vaccination with MCMVgp100KGP PMEL cells accumulate within the tumor tissue at high
frequency, suggestive of an “inflamed” tumor microenvironment. We also show upregulation of
several inhibitory pathways (PD-L1, Qa-1b, IDO1, and mo-MDSCs recruitment) following T cell
infiltration. Thus, at least by these parameters, our data suggests that vaccination against a
shared tumor antigen can produce an “inflamed” tumor phenotype.
Surprisingly, we were unable to enhance the efficacy of vaccination by checkpoint blockade or
inhibition of IDO. Expression of PD-L1 has been investigated as a predictive biomarker for
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response to antibodies blocking PD-1 or PD-L1.152 A previous study in murine pancreatic cancer
showed that vaccination induced expression of PD-L1 and synergized with PD-1 blockade;
however, this same study showed that tumors were also responsive to PD-1 blockade without
vaccination.174 Our results suggest that even in the presence of high levels of PD-L1, established
B16F10 tumors are still resistant to PD-1 blockade. Previous studies have shown that PD-1/PDL1 blockade can synergize with anti-CTLA-4 and IDO inhibitors.161,163 However, these studies
began combination therapy early after tumor challenge or in tumors expressing a foreign model
antigen. Our studies with B16ova show that presence of a foreign antigen can greatly impact the
efficacy of immunotherapy, but the relevance of these models to human disease is unclear. In
our studies, we show that the parental B16F10 model is much more resistant to immunotherapy.
To better model clinical disease, we also initiated therapy after tumors were visible and the
tumor microenvironment was established. These differences in experimental design may explain
the discrepancy in response to anti-PD-1 therapy in this tumor.
NKG2A is an inhibitory receptor expressed on the surface of NK cells and activated T
cells.153,155 The expression of its ligand, HLA-E, in human tumor cells prevents T cell-mediated
cytotoxicity through NKG2A engagement.154 Like MHC Class I molecules and PD-L1, HLA-E
and its murine homolog, Qa-1b, are upregulated in response to IFNγ.175,176 Our results show that
Qa-1b is highly upregulated in response to vaccination with MCMVgp100KGP. We also noted a
high percentage of PMEL cells expressing NKG2A within the tumor microenvironment,
suggesting a potential mechanism for immunoevasion. However, blockade of Qa-1b had no
effect on tumor growth following vaccination. A potential reason for this may be redundant
inhibitory checkpoint signaling through other receptors. In our studies, PMEL cells also express
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high levels of LAG3 and 2B4 within the tumor microenvironment. These pathways may also
restrict the efficacy of vaccine-stimulated T cells.
Several other counter-regulatory mechanisms may account for the resistance of B16F10 tumors
to vaccination. As we have shown, MCMVgp100KGP vaccination results in the recruitment of
Ly6C+ MDSCs to the tumor microenvironment. A previous study by Hosoi et al. showed that
adoptive transfer of tumor-specific T cells results in the recruitment of Ly6C+ MDSCs that limit
T cell function.156 We also noted a slight, but insignificant upregulation of IDO1 in tumor cells
following vaccination. IDO1 expression in tumor cells is known to induce the recruitment of
MDSCs in B16 tumors and increase resistance to immunotherapy.162 IDO inhibitors have been
evaluated in several preclinical tumor models and are currently being tested in combination with
checkpoint inhibitors in patients with metastatic melanoma (NCT02073123;
NCT02752074).161,163 Unfortunately, our initial experiments suggest that an IDO inhibitor with
or without anti-PD1 therapy does not prolong of mice vaccinated with MCMVgp100KGP.
In summary, this study shows that MCMV-based vaccines can significantly impact tumor growth
particularly when combined with adoptive cell transfer. Vaccines targeting foreign antigens
were more effective in tumor rejection, suggesting that MCMV-based vaccines targeting neoepitopes may be a more effective strategy to eliminate immunotherapy resistant tumors. Here,
we also show that several immunosuppressive pathways are upregulated in response to
MCMVgp100KGP vaccination, including PD-L1, Qa-1b, IDO1, and expansion of regulatory
immune cells. These pathways highlight an ongoing immune response within the tumor
environment and also suggested potential points of intervention for combination immunotherapy.
Unfortunately, we were unable to improve antitumor activity of MCMVgp100KGP vaccination
by inhibiting several of these pathways, suggesting that other pathways may be responsible for
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tumor relapse. We have not yet tested the effects of targeting MDSCs with MCMVgp100KGP
vaccination, but several studies have shown that targeting these cells can improve responses to
combination therapy.177,178 Tumor necrosis and hypoxia have also been shown to limit the
activity of antitumor T cells.179,180 In summary, this study shows that a persistent vaccine vector
can dramatically transform the phenotype of a “non-inflamed” tumor; however, expression of
several clinically-relevant immunosuppressive pathways following vaccination does not correlate
with increased sensitivity to inhibitors of these pathways. Future work looking at the role of
recruited MDSCs will investigate another potential role of resistance. Our data also suggests that
CMV-based vaccines targeting neo-epitopes may be a highly effective method for fighting
melanoma.
Figures:

Figure 4-1: Prophylactic but not therapeutic MCMVgp100KGP delays intradermal solid
tumor growth. A) Prophylactic vaccination with MCMVgp100KGP 7 days prior to challenge
with B16F10 cells significantly delays tumor growth. B) Therapeutic vaccination with
MCMVgp100KGP 3 days after tumor challenge does not significantly delay tumor growth.
n=5 mice/group for A) and 6-7 mice/group for B); n.s. Not significant; p>0.05; *p<0.05.
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Figure 4-2: Vaccination increases number and activation status of CD8+ TIL but does not
influence inhibitory receptor expression. Mice were treated with MCMVgp100KGP 3 days
after tumor challenge and TIL were harvested 15 days later for flow cytometry. Vaccination
increases A) total number of CD8+ TIL and B) expression of CD11a on CD8+ TIL. Vaccination
does not change C) percentage of CTLA-4+CD8+ TIL, D) CTLA-4 MFI on CD8+ TIL, E)
percentage of PD-1+ CD8+ TIL, and E) PD-1 MFI on CD8+ TIL. n=5-6/group; **p<0.01.

59

Figure 4-3: Checkpoint blockade does not synergize with therapeutic MCMVgp100KGP
vaccination. A) Experimental schema for B) and C). Three days after tumor challenge, mice
were vaccinated with MCMVgp100KGP or mock vaccinated and treated with B) anti-PD-1 on
days 6, 9, and 12 or C) anti-CTLA-4 on days 3, 6, and 9. Control mice received isotype control
antibodies.
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Figure 4-4: MCMVova stimulates adoptively transferred OT-I cells but does not maintain
them long-term. C57BL/6 mice received 105 CD45.1+ OT-I CD8+ T cells i.v. followed by
vaccination with 105 PFU WT MCMV or MCMVova i.p. A) Seven days after transfer, OT-I
cells are found at high frequency in peripheral blood of mice vaccinated with MCMVova but not
WT MCMV. B) OT-I cells display an effector memory phenotype (KLRG1+CD127lo) seven
days after transfer. C) Frequency of OT-I cells in peripheral blood of MCMVova vaccinated
mice from two separate experiments. One of nine mice showed a high frequency of OT-I cells
four months after vaccination. Results are representative of two independent experiments.
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Figure 4-5: Adoptive cell therapy and MCMVova cure mice with established B16ova
tumors. Mice bearing B16ova tumors were treated with 105 naïve OT-I cells, vaccination with
MCMVova, OT-I transfer and WT MCMV vaccination, or OT-I transfer and MCMVova
vaccination. A) Tumor growth curves of individual mice in each treatment group. B) Survival
curves of treated mice. Results are representative of 3 independent experiments with 5
mice/group. ***p<0.001
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Figure 4-6: MCMVgp100KGP stimulates adoptively transferred PMEL cells. A) C57BL/6
mice received 105 CD8+ Thy1.1+ PMEL cells followed by vaccination with PBS, WT MCMV,
MCMVgp100, or MCMVgp100KGP. Frequency of Thy1.1+ cells in peripheral blood five days
after vaccination. B) Frequency of Thy1.1+ cells in peripheral blood of mice vaccinated with
MCMVgp100KGP. C) Frequency of Thy1.1+ cells in peripheral blood of mice vaccinated with
MCMVgp100KGP or VSVgp100KGP 5 or 160 days after vaccination. n=3 mice/group;
**p<0.01
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Figure 4-7: MCMVgp100KGP maintains PMEL cells in lungs long-term. Transferred PMEL
cells are detected in lungs of mice vaccinated with MCMVgp100KGP but not VSVgp100KGP
263 days following transfer. A) Flow cytometry plots from individual mice. B) Representative
plot showing effector memory phenotype of PMEL cells in lungs of mice vaccinated with
MCMVgp100KGP 263 days prior. n=3 mice/group.
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Figure 4-8: Adoptive cell therapy and MCMVgp100KGP vaccination delays growth of
established B16 tumors. Mice were challenged with B16F10 5 days prior to transfer of 105
CD8+ PMEL cells and vaccination with WT MCMV or MCMVgp100KGP. A) Individual tumor
growth curves. B) Combined tumor growth curves. Statistical differences are noted as:
PMEL+MCMVgp100KGP vs. Mock Treated *; PMEL+MCMVgp100KGP vs. PMEL *;
PMEL+MCMVgp100KGP vs. PMEL+WT MCMV*; PMEL+MCMVgp100KGP vs.
MCMVgp100KGP*. C) Survival curves. Data was combined from two independent
experiments with 5 mice/group. One mouse from PMEL+MCMVgp100KGP group did not
grow a tumor over the course of the experiment and was excluded from the analysis. *p<0.05;
**p<0.01
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Figure 4-9: MCMVgp100KGP stimulated T cells upregulate inhibitory receptors in tumor
microenvironment. Tumor bearing mice were treated with PMEL transfer and
MCMVgp100KGP vaccination. Six days later, blood and tumor tissue were harvested for flow
cytometry. A). Representative plots showing expression of inhibitory receptors on PMEL cells
from blood or tumor in the same mouse. B) MFI of inhibitory receptors on PMEL cells from
blood compared to MFI on PMEL cells isolated from tumors in the same mouse. n=4 mice.
Data representative of at least 2 independent experiments. *p<0.05; ***p<0.001
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Figure 4-10: Combination immunotherapy induces expression of inhibitory ligands in vivo.
Five days after challenge with B16RFP, mice were left untreated, treated with PMEL transfer
and WT MCMV vaccination, or treated with PMEL transfer and MCMVgp100KGP vaccination.
Six days later, tumor cells were harvested for flow cytometry. A) Representative flow plots of
RFP+ cells. B) Percentage of RFP+ cells expressing C) PD-L1 and D) both PD-L1 and Qa-1b. D)
Representative plots of CD45+CD8-RFP- cells. Percentage of CD45+CD8-RFP- cells
expressing A) PD-L1 and B) both PD-L1 and Qa-1b. Representative of two independent
experiments with n=4-5 mice/group. *p<0.05; ***p<0.001

68

Figure 4-11: PD-1 and Qa-1b blockade do not enhance antitumor effects of
MCMVgp100KGP immunotherapy. Mice were challenged with B16F10 and five days later
treated with PMEL transfer and MCMVgp100KGP vaccination. Mice received anti-PD-1, antiQa-1b, or both on day 10, 12, and 14. Untreated mice or mice receiving monotherapy also
received isotype control antibodies. A) Individual tumor growth curves and B) survival curves
of mice receiving combination immunotherapies. Data combined from two independent
experiments. n=10 mice/group.
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Figure 4-12: MCMVgp100KGP vaccination induces accumulation of monocytic MDSCs.
Mice bearing B16F10 tumors were left untreated, treated with PMEL transfer and WT MCMV
vaccination, or treated with PMEL transfer and MCMVgp100KGP vaccination. Six days after
treatment, tumors were processed for flow cytometry. Numbers of A) Thy1.1+ PMEL cells, B)
Gr-1+CD11b+ cells, C) Ly6C+CD11b+ cells, and D) Ly6G+CD11b+ cells were normalized to
initial tumor weight. A, C, and D are representative of three independent experiments with n=45 mice/group. B is representative of one experiment. *p<0.05; **p<0.01; ***p<0.001
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Figure 4-13: MCMVgp100KGP vaccination slightly upregulates expression of IDO in
tumor cells. Mice were inoculated with B16RFP tumors via intradermal injection and 5 days
later left untreated, treated with PMEL transfer and WT MCMV vaccination, or treated with
PMEL transfer and MCMVgp100KGP vaccination. Six days later tumors were processed for
flow cytometry. A) Percentage of RFP+ tumor cells expressing IDO. B) MFI of IDO in RFP+
tumor cells relative to isotype control. C) Representative figure of IDO expression in RFP+
tumor cells. Data for A) and B) were compiled from two independent experiments with 9-10
mice/group.
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Figure 4-14: IDO inhibitor does not enhance response to combination immunotherapy.
Mice were challenged with B16F10 tumors and were treated with PMEL transfer and
MCMVgp100KGP vaccination five days later. On day 10, mice were started on 2mg/mL 1methyltryptophan (1-MT) in the drinking water or control water. Mice were also treated with
anti-PD1 or isotype control on days 10, 13, and 18. n=5 mice/group.
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Figure 4-13: Combination chemo-immunotherapy significantly delays tumor growth. A)
Schematic of experimental design. Mice were challenged with B16F10 six days prior to
receiving one dose of cyclophosphamide. On day 7, mice received 105 in vitro activated PMEL
cells and vaccination with WT MCMV or MCMVgp100KGP. B) Tumor growth curves and C)
survival curves show combination chemo-immunotherapy significantly delays growth of
established tumors. Data is representative of 3 independent experiments with n=5 mice/group.
***p<0.001
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Chapter 5: Identification of Novel CD169+ Macrophage Population
within Melanoma Tumors
Abstract:
Malignant tissue is often inundated with myeloid cells of diverse phenotype. Tumor associated
macrophages make up a large proportion of tumor myeloid cells and generally are thought to
promote tumor progression. Macrophages expressing the marker CD169 have critical roles in
filtering lymph in lymph nodes and blood in the spleen and are thought to be critical to initiating
the adaptive immune response. Here we show that CD169+ macrophages are present in high
frequency in murine melanoma and these macrophages are phenotypically distinct from skin
resident macrophages, and preferentially ingest tumor particles. Future work will determine the
effect of CD169+ macrophages in tumor growth.
Introduction:
Cancerous tissue is often infiltrated by high frequencies of myeloid cells. Tumor associated
macrophages (TAMs) are a diverse group of cells making up a large percentage of tumor
infiltrating leukocytes.181,182 In many cancers, increasing frequencies of TAMs are associated
with reduced overall survival.183 This association has also been confirmed in patients with
melanoma, leading to the predominate hypothesis that TAMs are generally protumorigenic.184
The plasticity of macrophages under diverse environmental conditions often makes the study of
their functions difficult, particularly in vivo.185 However, studies have shown that TAMs can
influence tumor growth through a variety of mechanisms, including increased tumor
angiogenesis, promotion of metastasis and invasive characteristics of tumor cells, and
suppression of antitumor T cell responses.186
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CD169+ macrophages represent a subset of myeloid cells largely studied within lymphoid
tissues. Within the spleen and lymph nodes, CD169+ macrophages act as filters to capture
microbes and exposed antigens in blood or lymph, initiating the activation of lymphocytes within
these tissues.187 A handful of studies have begun to investigate the role of these cells in tumor
immunity. A study by Asano et al. showed that CD169+ macrophages in the draining lymph
nodes of mice phagocytose dead tumor cells following subcutaneous vaccination, and these cells
are required for vaccine efficacy by cross-presenting tumor antigen and priming antitumor T
cells.188 Similarly, a study by Pucci et al. showed that CD169+ macrophages within lymph nodes
captured extracellular vesicles produced by tumor cells, and this capture prevented activation of
tumor-promoting B lymphocytes.189
Several clinical studies have also illustrated the significance of CD169+ lymph node
macrophages as predictive biomarkers for cancer progression.190,191 In melanoma patients,
specifically, higher densities of these macrophages in regional lymph nodes correlated with
prolonged survival and greater infiltration of tumor tissue by CD8+ T cells.192 Like the mouse
models, these studies suggest that CD169+ macrophages in lymphoid tissue are involved in
priming antitumor T cells. In the current study, we show for the first time that CD169+
macrophages are not only localized to draining lymph nodes but are also found directly within a
solid melanoma tumor. These cells appear in high frequency in the tumor tissue, are
phenotypically distinct from skin-resident macrophages, and may phagocytose tumor cell
particles more efficiently than CD169- TAMs.
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Results:
Intradermal B16 tumors contain a novel CD169+ macrophage subset that are distinct from skin
resident macrophages
Given the diversity of myeloid cells seen in different tumors and the potential of CD169+
macrophages to elicit antitumor immunity in lymph nodes, we asked whether B16F10 melanoma
tissue contained CD169+ TAMs. Surprisingly, B16F10 tumors were inundated with CD169+
cells (Figure 5-1). These cells were F4/80+ by immunofluorescence imaging and flow
cytometry, confirming their identity as TAMs (Figures 5-1 and 5-2A). CD169+ TAMs expressed
high levels of Fc gamma receptor 1 (CD64) and CSF1R (CD115), further confirming their
myeloid identity (Figure 5-2B). Interestingly, CD169+ TAMs expressed only low levels of
CCR2 which is a key chemokine receptor for monocyte recruitment (Figure 5-2B).
Impressively, CD169+ TAMs uniformly expressed high levels of MHCII, while CD169-F4/80+
TAMs contained a significant MHCIIlo population (Figure 5-2C).
Intradermal CD169+ macrophages are phenotypically distinct from skin resident macrophages
Previous studies have shown that tumor tissue contains both tissue-resident macrophages and
monocyte-derived macrophages.181 CD169+ macrophages have been described in healthy skin,
predominately within the dermal layer.193,194 We therefore asked if CD169+ TAMs were
phenotypically distinct from skin resident macrophages. Like previous studies, we detected a
subpopulation of macrophages in skin from naïve mice expressing CD169 (Figure 5-3A). Skin
resident CD169+ macrophages contained a distinct CD11c+MHCII+CCR2+ subpopulation (Figure
5-3B). In contrast, CD169+ TAMs uniformly expressed MHCII and low levels of CCR2 (Figure
5-3C), showing that CD169+ TAMs are phenotypically distinct from skin resident macrophages.
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As previously stated, the majority of TAMs in other tumor models are derived from recruited
circulating monocytes.181 We hypothesize that CD169+ TAMs are also derived from circulating
monocytes rather than skin resident macrophages. Future studies will examine this more closely.
CD169+ TAMs ingest tumor particles within the tumor microenvironment
As already stated, CD169+ macrophages in lymphoid tissues are thought to efficiently
phagocytose tumor derived particles by filtering draining lymph.188,189 We therefore
hypothesized that CD169+ TAMs might also efficiently internalize tumor fragments. To test
this, mice were inoculated via intradermal injection with B16F10 expressing Red Fluorescent
Protein (B16RFP). Eleven days later, tumor tissue was harvested and processed for flow
cytometry. As hypothesized, some CD169+ macrophages also expressed low levels of RFP,
suggesting internalization of tumor fragments (Figure 5-4A). Impressively, of all F4/80+ cells
co-expressing RFP, the majority were CD169+, signifying preferential phagocytosis by CD169+
TAMs (Figure 5-4B). We also noted high expression of MHCII and the costimulatory ligand,
CD80 on CD169+ macrophages, suggesting a preferential ability to prime T cells (Figure 5-4C).
While this flow cytometry data suggests internalization of tumor fragments by CD169+
macrophages, it is possible that these macrophages take up tumor fragments during processing
for flow cytometry. We therefore stained fixed sections of B16RFP tumors for CD169. Imaging
revealed many CD169+ TAMs in close association with RFP+ tumor cells (Figure 5-5) and some
contained punctate RFP+ signals, confirming internalization of tumor particles in vivo (Figure 56). Thus, CD169+ macrophages may be well-equipped to internalize and process tumor antigen
not only at lymphoid tissues but also within the tumor microenvironment.
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Discussion:
Infiltration of tumor tissue by macrophages has been associated with poor prognosis for patients
with several types of malignancy.183,184 The mechanisms behind this observation are probably
diverse as TAMs can influence disease progression through several pathways including
angiogenesis and immunosuppression.186 Tumor tissue can contain several subsets of
macrophages with different phenotypic characteristics. Some of these macrophages are derived
from proliferating tissue-resident macrophages, but the majority of TAMs are thought to
originate from blood-derived monocytes that differentiate within the tumor microenvironment.181
Lymph node resident CD169+ macrophages have been implicated in the priming of antitumor
immunity in preclinical models by capturing and cross-presenting tumor antigen to prime
antitumor T cells.188 In patients, the density of these cells in regional lymph nodes correlates
with increased T cell infiltration of tumor tissue and increased overall survival.190-192 Thus,
CD169+ cells within the lymph node appear to be critical in regulating antitumor immunity.
In this study, we discovered that a significant number of cells express CD169 within the tumor
microenvironment. These cells were confirmed to be TAMs by co-staining for the macrophage
markers, CD64 and F4/80. While our data shows that CD169+ TAMs are phenotypically distinct
from skin resident macrophages, it is still unclear whether CD169+ TAMs arise from skin
resident macrophages that respond to the growing tumor or whether they differentiate from
circulating peripheral monocytes. Future studies will dissect the origin of these cells.
CD169+ TAMs uniformly expressed high levels of MHCII and CD80, suggesting a potential
ability to activate antitumor T cells. In contrast, CD169- TAMs contained populations of
MHCIIlo and MHCIIhi cells and expressed lower levels of CD80. Surprisingly, our preliminary
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data also suggests an ability of CD169+ cells to ingest fragments of tumor cells. With these
properties, we hypothesize that CD169+ TAMs have the ability to stimulate rare antitumor T
cells within the tumor microenvironment. A previous study using clinical samples from patients
with hepatocellular carcinoma has also described CD169+ TAMs which express high levels of
HLA-DR and CD86. This same study also showed that the density of CD169+ TAMs correlated
with intratumoral CD8 T cell density and overall patient survival.195 Our future studies will test
the ability of CD169+ TAMs to stimulate antitumor T cells and investigate the role of these cells
in melanoma tumor progression.

Figure 5-1: Intradermal B16F10 tumors contain a high density of CD169+ TAMs. Mice
were inoculated with B16F10 tumor cells via intradermal injection. Established tumors were
fixed in PLP buffer and cut into 20µm sections before staining antibodies against CD169 (red),
F4/80 (dark blue), CD8 (light blue). Scale bar=50µm.
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Figure 5-2: Phenotypic characterization of CD169+ TAMs. Intradermal B16F10 tumors were
processed into single cell suspension and stained for flow cytometry. A) CD169 staining of
tumor infiltrating leukocytes, gated on live CD45+ cells. B) CD169+ TAMs express CD115,
CD64, and low levels of CCR2. C) CD169+ TAMs express high levels of MHCII, while CD169TAMs show diverse MHCII expression. n=3 mice. Representative of at least two independent
experiments, except CD64 staining which is representative of one experiment.
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Figure 5-3: Skin resident CD169+ macrophages are phenotypically distinct from TAMs. A)
CD169+ macrophages are found in skin from healthy mice. B) CD169+ macrophages from
healthy skin consist of two populations: MHCII+CCR2+CD11c+ and MHCII-CCR2-CD11cpopulations. C) CD169+ TAMs from B16F10 tumors are uniformly MHCII+ and express low
levels of CCR2 and CD11c. n=3 mice/group.
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Figure 5-4: CD169+ TAMs engulf tumor particles in untreated solid tumors. Mice were
inoculated with B16RFP. Tumors and spleen were harvested 11 days later for flow cytometry.
A) CD169+ F4/80+ TAMs show increased fluorescence in the RFP channel compared to CD169F4/80+ TAMs from the same tumors. B) The majority of RFP+ TAMs are CD169+. RFP gating
was based on staining in spleen which should not contain RFP+ cells. C) CD80 expression on
CD169+ TAMs and CD169- TAMs. n=4 mice.
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Figure 5-5: CD169+ TAMs interact with B16RFP tumor cells in close proximity. Mice were
inoculated with B16RFP tumors and 11 days later, tumors were PLP fixed, sectioned into 20µm
sections, and stained for CD169. Top row shows B16RFP tumors without CD169 staining.
Bottom two rows show RFP (red) and CD169 (blue) in close proximity within the tumor.
Arrows indicate CD169+ TAMs in close proximity to B16RFP tumor cells. n=2 mice; Scale
bar=80µm.
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Figure 5-6: CD169+ TAMs ingest RFP+ tumor particles within the tumor
microenvironment. Mice were inoculated with B16RFP tumor cells and 11 days later tumors
were harvested and fixed by PLP fixation. Tumors were cut into 20µm sections and stained for
CD169. Arrows indicate CD169+ TAMs (blue) with internalized RFP+ particles (red). n=2 mice;
Scale bar=80µm.
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Chapter 6: Summary and Future Directions
Cytomegalovirus-based Tumor Vaccines
Cytomegalovirus (CMV) is a ubiquitous herpes virus that generates a unique T cell response
termed “memory inflation”. This phenomenon is characterized by the maintenance of a high
frequency of virus-specific T cells over the lifetime of the host. In contrast to other chronic
infections, CMV-specific T cells maintain effector function over time.95,105 Impressively, this
unique T cell response is still observed after vaccination with a single-cycle virus, limiting the
danger of viral reactivation.116 These properties make CMV an attractive platform for vaccines
targeting infectious diseases and cancer.
Our lab has previously generated a Murine Cytomegalovirus (MCMV) vaccine vector expressing
an alter melanoma antigen (MCMVgp100KGP) that delays murine melanoma growth.129 In this
study, we sought to generate a novel MCMV vaccine expressing both gp100KGP and a second
altered melanoma antigen. In the process, we show that a MCMV based vaccine expressing both
gp100KGP and the native melanoma antigen, Trp2 is unable to delay tumor growth compared to
MCMVgp100KGP, highlighting the difficulty of vaccinating against self-antigens. We
anticipated this result and therefore simultaneously constructed a MCMV vector expressing
gp100KGP and an altered Trp2. However, by altering Trp2 at one amino acid, we drastically
reduced the expression of the full-length protein. Not surprisingly, this vector also did not
improve antitumor activity compared to MCMVgp100KGP. While this study did not generate a
more effective melanoma vaccine, it does highlight a potential pitfall in altering T cell epitopes
within full-length proteins in an expression vector. A previous study by Klyushnenkova et al.
showed that a MCMV-based vaccine expressing a T cell epitope in prostate-specific antigen was

85

more effective than one expressing the full-length protein.126 Thus, future CMV-based vaccines
may be more effective if designed to express shorter peptides corresponding to T cell epitopes
rather than full-length proteins. Another potential pitfall for CMV-based vaccines may be the
incorporation of several epitopes within the same vaccine vector. Research has shown that
inserting a foreign antigen into a MCMV vector reduces the endogenous virus-specific
inflationary T cell response. However, when these epitopes are expressed in two different
viruses, inflationary T cell responses were not restrained, suggesting that inflationary epitopes
compete within infected cells for antigen presentation.196 Thus, targeting different tumor
antigens using several CMV-based vectors may be more effective than multiple-epitope vectors.
Future work will test several MCMV-based vaccines each expressing altered T cell epitopes
within established melanoma antigens. In addition, targeting novel epitopes created as a result of
tumor mutation (termed neo-epitopes) may yield more dramatic results. As methods for
predicting immunogenic neo-epitopes improves, CMV-based vaccines may be an effective
vaccine formulation to induce lifelong T cell responses specifically recognizing tumor antigen.
Combining CMV-based Vaccines with Other Immunotherapies
This study extends previous work by our lab investigating the impact of MCMV-based vaccines
for the treatment of melanoma. Herein, we show that MCMV expressing tumor antigens can
delay tumor growth in an aggressive solid tumor model of B16 melanoma. We also show that
vaccine efficacy is limited by the precursor frequency of tumor-reactive T cells. As
hypothesized, combining MCMV vaccination with adoptive cell therapy significantly delays
tumor growth compared to either therapy alone.
In this study, we also show that combination adoptive cell transfer and MCMV vaccination
significantly upregulates the expression of several immunosuppressive pathways directly within
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the tumor microenvironment. B16 melanoma is generally considered to be a non-immunogenic
tumor model as checkpoint inhibitor monotherapy has little effect on established tumor
growth.163,197 Clinical responses to immune checkpoint therapy has been associated with
increased T cell infiltration, mutational load, and PD-L1 expression.39,41,76 This has led scientists
to distinguish tumors as “inflamed” or “non-inflamed” based on the presence of T cell infiltrate
and inhibitory pathway expression.143 Our data suggests that CMV-based vaccination can at
least partly induce an “inflamed” phenotype in an aggressive tumor model. However, in contrast
to clinical studies suggesting that expression of inhibitory ligands in the tumor
microenvironment, we did not discover enhanced responsiveness to PD-1, NKG2A, or IDO
inhibition following vaccination, despite high expression of several of these pathways. As
previously discussed, several other pathways may be limiting vaccine efficacy, including
expression of other inhibitory receptors like LAG-3 and 2B4 or recruitment of regulatory cells
like MDSCs. Molecules targeting these pathways may be useful in this tumor model. For
instance, CSF1R antagonists have been shown to limit the influence of MDSCs within the tumor
microenvironment.178 More broadly, several studies have noted that tumor necrosis and tissue
hypoxia can limit T cell activity within the tumor microenvironment, providing other potential
mechanisms for immune resistance.179,180,198 Future studies will determine if inhibitors of these
pathways may enhance antitumor activity of MCMV-based vaccines.
The most promising results from our studies include the eradication of tumors in mice treated
with adoptive cell therapy and MCMVova. This data suggests that CMV-based vaccines
targeting neo-epitopes may be highly effective immunotherapies, even in these highly aggressive
tumors. One study has already tested traditional peptide-based vaccines targeting neo-epitopes
in B16 melanoma, showing a significant delay in tumor growth.35 These results may be even
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more dramatic in the context of an inflationary T cell response against these epitopes. Thus,
future work will seek to generate several MCMV-based vaccines targeting tumor-specific
antigens.
Elucidating the Role of CD169+ Macrophages within the Tumor Microenvironment
Tumor associated macrophages (TAMs) make up a large frequency of tumor infiltrating
leukocytes and have generally been associated with poor prognosis in several cancers.183,184 In
contrast, CD169+ macrophages within the regional lymph nodes seem to contribute to antitumor
immunity, as higher densities of these macrophages correlate with CD8+ T cell infiltration of
tumor tissue and overall survival in melanoma.192 In preclinical models, these cells are essential
for capturing tumor antigen within the draining lymph node and activating CD8+ T cells while
preventing activation of tumor-promoting B cells.188,189
Here, we have shown that CD169+ macrophages are also found at relatively high frequency
directly within B16 melanoma tumors. Few studies have described this subpopulation of
macrophages directly within the tumor microenvironment. In one such study, CD169+ TAMs in
hepatocellular carcinomas displayed high levels of MHCII and CD86, and CD169+ TAM density
correlated with CD8+ T cell infiltration and overall patient survival, suggesting a critical role for
these macrophages in antitumor immunity.195 In our own current study, we show that CD169+
TAMs from B16F10 tumors also express high levels of MHCII and the costimulatory molecule
CD80. Impressively, we also show preliminary evidence that CD169+ TAMs can engulf tumor
particles directly within the tumor microenvironment. All of these results lead us to hypothesize
that CD169+ TAMs may represent a subpopulation of TAMs capable of capturing and presenting
tumor antigen to T cells directly within the tumor microenvironment. We have already begun
trying to record CD169+ TAM capture of tumor particles using intravital two photon imaging and
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CD169 reporter mice to further confirm this ability in these cells. Future work will also test the
ability of these cells to stimulate T cells. By FACS sorting CD169+ and CD169- TAMs directly
from B16 tumors, we will compare the ability of these two populations to stimulate T cells ex
vivo. If our hypothesis is correct and CD169+ TAMs do stimulate antitumor T cells, therapies
aimed at increasing this TAM subpopulation may greatly impact cancer progression or
responsiveness to other cancer immunotherapies.
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